Next Article in Journal
Sequence, Chromatin and Evolution of Satellite DNA
Next Article in Special Issue
Increased Osteocyte Lacunae Density in the Hypermineralized Bone Matrix of Children with Osteogenesis Imperfecta Type I
Previous Article in Journal
New Succinimides with Potent Anticancer Activity: Synthesis, Activation of Stress Signaling Pathways and Characterization of Apoptosis in Leukemia and Cervical Cancer Cells
Previous Article in Special Issue
Hesperidin Promotes Osteogenesis and Modulates Collagen Matrix Organization and Mineralization In Vitro and In Vivo
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 9
10.3390/ijms22094321
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Signaling Pathways in Bone Development and Their Related Skeletal Dysplasia

by
Alessandra Guasto
1 and
Valérie Cormier-Daire
1,2,*
1
Imagine Institute, Université de Paris, Clinical Genetics, INSERM UMR 1163, Necker Enfants Malades Hospital, 75015 Paris, France
2
Centre de Référence Pour Les Maladies Osseuses Constitutionnelles, Service de Génétique Clinique, AP-HP, Hôpital Necker-Enfants Malades, 75015 Paris, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(9), 4321; https://doi.org/10.3390/ijms22094321
Submission received: 16 March 2021 / Revised: 12 April 2021 / Accepted: 19 April 2021 / Published: 21 April 2021
(This article belongs to the Special Issue Osteoblast Differentiation and Activity in Skeletal Diseases)
Browse Figures
Versions Notes

Abstract

:
Bone development is a tightly regulated process. Several integrated signaling pathways including HH, PTHrP, WNT, NOTCH, TGF-β, BMP, FGF and the transcription factors SOX9, RUNX2 and OSX are essential for proper skeletal development. Misregulation of these signaling pathways can cause a large spectrum of congenital conditions categorized as skeletal dysplasia. Since the signaling pathways involved in skeletal dysplasia interact at multiple levels and have a different role depending on the time of action (early or late in chondrogenesis and osteoblastogenesis), it is still difficult to precisely explain the physiopathological mechanisms of skeletal disorders. However, in recent years, significant progress has been made in elucidating the mechanisms of these signaling pathways and genotype–phenotype correlations have helped to elucidate their role in skeletogenesis. Here, we review the principal signaling pathways involved in bone development and their associated skeletal dysplasia.

1. Introduction

Skeletal development in mammals occurs through two distinct mechanisms: intramembranous and endochondral ossification. In the intramembranous process, osteoblast cells differentiate directly from mesenchymal cells and form flat bones like cranial vault, parts of the jaw and lateral clavicles. At the end of the bone formation period, osteoblasts die by apoptosis or become embedded in the matrix as osteocytes, which then eventually undergo apoptosis [1]. In the endochondral process, which forms the rest of the skeleton, the mesenchymal cells condensate and differentiate in chondrocytes that deposit a cartilaginous model. Then, chondrocytes proliferate, forming the growth plate and secreting a cartilage-specific extracellular matrix. Afterwards, chondrocytes in the center of the cartilage arrest to divide and increase their volume, becoming hypertrophic chondrocytes [2,3]. The hypertrophic chondrocytes have the capacity to mineralize their extracellular matrix and can die by apoptosis or differentiate into osteoblasts. With the invasion of the cartilage model by blood vessels, stem cells of different lineages give rise to the bone depositing osteoblasts and the bone resorbing osteoclasts forming the primary ossification center. After formation of a secondary ossification center within the cartilaginous epiphyses during the early postnatal stage, the definitive growth plate can be identified by well-demarcated zones of cells representing the maturation steps of chondrocytes (resting, proliferative, prehypertrophic and hypertrophic) and remains, in humans, until puberty.
Both ossification processes are strictly regulated by several signaling pathways grouped by their response to the following signaling ligand families: Hedgehog (HH), Parathyroid Hormone-related Protein (PTHrP), Wingless and int-1 (WNT), NOTCH, Transforming Growth Factor-beta (TGF-β), Bone Morphogenic Protein (BMP) and Fibroblast Growth Factor (FGF). These pathways converge on specific transcription factors including SRY-related HMG-box 9 (SOX9), Runt-related transcription factor 2 (RUNX2) and Osterix (OSX). Dysregulation of these signaling pathways cause a large spectrum of skeletal diseases. Skeletal dysplasia (SD), also named osteochondrodysplasia, is a group of rare genetic disorders mainly characterized by cartilage and bone growth anomalies. Today, thanks to next-generation DNA sequencing, 461 different SD have been recognized and classified in 42 groups depending on their clinical, radiographic and/or molecular bases [4]. Here, we review the most important signaling pathways involved in bone development and the SD associated with signaling impairment. All SD mentioned in this review are listed in Table 1.

2. Hedgehog Signaling

Hedgehog (HH) signaling is involved in many developmental processes, such as growth, patterning and morphogenesis of many tissues. In mammals, three HH ligands are produced: Sonic (SHH), Indian (IHH), and Desert Hedgehog (DHH). HH ligands interact with the 12-pass transmembrane Patched receptors (PTCH 1 and 2) causing the activation of the smoothened (SMO) protein, a 7- pass transmembrane protein with intrinsic intracellular activity. Its translocation to the base of primary cilium activates Gli transcriptor factors (GLI 1, 2 and 3) [5,6,7]. In vertebrates, SHH and IHH are the principal ligands involved in skeletal development. SHH is involved in the first stages of mesenchymal condensation. It promotes the epithelial-mesenchymal transition of sclerotome, the skeletogenic mesenchyme from which the intervertebral discs, vertebrae and ribs are derived [8,9]. SHH is also expressed in the developing face and regulates the outgrowth and the differentiation of the cranial-neural crest cell-derived skeletal structures [10,11]. Moreover, SHH have a critical role in digit patterning in the appendicular skeleton [12]. On the other hand, IHH is implicated in skeleton formation and in particular in endochondral ossification [5,6]. IHH is strongly expressed in the growth plate by pre- and early hypertrophic chondrocytes. It regulates chondrocyte hypertrophy in an indirect manner through a negative feedback loop with parathyroid hormone-related peptide (PTHrP), and directly promotes chondrocyte proliferation and osteoblast specification (Figure 1A) [13,14,15].
In the first case, IHH upregulates the expression of PTHrP, which maintains growth plate chondrocytes in a proliferative state and inhibits their hypertrophic maturation [16]. Indeed, the maintenance of proliferation promoted by PTHrP inhibits IHH production, since it is expressed by prehypertrophic chondrocytes and not by proliferative chondrocytes [15,17]. In the second case, IHH promotes chondrocyte proliferation in a direct manner by inhibiting the GLI3 activity and promoting the transition of round chondrocyte into proliferating chondrocytes [14,18].
HH is also involved in osteoblast development during ossification. In endochondral ossification, IHH produced by pre-hypertrophic and hypertrophic chondrocytes acts on osteoblast progenitors to induce the specification in Runx2-positive osteoblast precursors in the perichondrium and the primary spongiosa [19,20]. In addition to osteoblast differentiation in the perichondrium, HH signaling is also fundamental for trabecular bone formation [21].
As demonstrated by all these studies, HH signaling is critical for bone development and its misregulation results in several human skeletal diseases associated with a wide spectrum of limb and facial skeletal anomalies. In particular, as mentioned before, HH ligands diffuse across the developing limb bud and produce a concentration gradient that acts as a morphogen to specify digit development. HH signaling activating mutations, like those inactivating GLI3 repressor, cause polydactyly in Greig cephalopolysyndactyly syndrome, Pallister-Hall syndrome and Preaxial polydactyly type 4 [22,23,24,25,26], while missense heterozygous mutations in IHH cause brachydactyly type A1 [24,25,27]. Mutations in IHH have also been associated with Syndactyly with craniosynostosis [28], Syndactyly Lueken type [29] and acrocapitofemoral dysplasia [30]. This last disorder is caused by missense mutations causing an increased chondrocyte differentiation by diminishing IHH signaling in the growth plate. The phenotype is characterized by short stature with short limbs and highlights the importance of IHH in coordinating chondrocyte proliferation and differentiation. On the other hand, SHH mutations cause congenital hand deformities and severe craniofacial and neurological syndromes like Werner syndrome, Acheiropodia [31], different forms of polydactyly and syndactyly [32], and Laurin-Sandrow syndrome [33].

3. Parathyroid Hormone-Related Protein

PTHrP is a paracrine factor expressed by cartilage and bone. In particular, PTHrP is expressed by periarticular resting cells of the perichondrium and at a lower level by proliferating chondrocytes [19,34]. PTHrP binds to a specific receptor (PTHR1), which is G-protein coupled and is composed of seven transmembrane domains [35]. PTHR1 is expressed at low levels by proliferating chondrocytes and at a higher level in prehypertrophic chondrocytes [17,19]. Upon ligand binding, receptor activation results in stimulation of the heteromeric (αβγ) guanine nucleotide binding proteins (Gαs and Gαq). Through Gαs, PTHrP receptor activates adenylate cyclase (AC) and the production of 3’, 5’-adenosine monophosphate (cAMP), which in turn activates protein kinase A (PKA) [27,36]. On the other hand, stimulation of Gαq activates phospholipase Cβ (PLCβ) and the formation of diacylglycerol (DAG) and 1,4,5-inositol triphosphate (IP3). DAG activates in turn proteinase kinase C (PKC), while the production of IP3 leads to an increase of intracellular Ca2+ [37,38].
These two signaling pathways have opposite actions on chondrocyte differentiation (Figure 1B). PTHrP uses AC/cAMP/PKA pathway to keep chondrocyte proliferating and to promote the activation of the transcriptor factor SOX9, that restrains chondrocyte differentiation [39,40,41]. In addition, PKA inhibits the expression of the myocyte enhancer factor 2 (MEF2) and of RUNX2, two key transcription factors promoting chondrocyte hypertrophy via the recruitment of the class II histone deacetylase HDAC4 in the nucleus [42]. In contrast, PLC/IP3 signaling via the PTH/PTHrP receptor appears to restrain proliferation of chondrocytes and to stimulate their progression toward hypertrophic differentiation [43]. PTHrP is also produced by early osteoblast precursors and actively synthetizing osteoblasts. It has been showed that periosteum-derived PTHrP induced osteoblast activity and bone formation [44,45,46].
The critical role of PTHrP receptor in bone development is highlighted by the discovery of two severe chondrodysplasias: Blomstrand lethal chondrodysplasia and metaphyseal chondrodysplasia Jansen type. Inactivating recessive PTHR1 mutations in Blomstrand dysplasia cause prenatal lethality, shortened limbs, advanced bone mineralization and increased bone density due to reduction of proliferating and resting chondrocytes within the growth plate [47,48]. Metaphyseal chondrodysplasia Jansen type, meanwhile, is caused by activating mutations that lead to ligand-independent activation of PTHR1 and of the cAMP pathway. This causes a phenotype characterized by severe abnormalities of the growth plate, short-limbed dwarfism, micrognatia and hypercalcemia [49]. Interestingly, a homozygous truncating mutation in PTHR1 has been identified in Eiken dysplasia, a disorder with opposite phenotype compared to Blomstrand dysplasia. Patients with Eiken dysplasia show severely delayed skeletal maturation, as well as mild growth retardation [50]. These findings demonstrate that distinct recessive mutations in the same gene can generate contrasting phenotypes. Another connection between human genetic bone disorder and PTHrP signaling is shown in brachydactyly type E, caused by loss-of-function mutations in parathyroid hormone-like hormone (PTHLH), a PTHR1 ligand, and characterized by bone shortening of hands and feet [51]. A more severe brachydactyly phenotype is also found in acrodysostosis, in association with facial dysostosis, nasal hypoplasia and developmental delay. This disease is caused by mutations in PRKAR1A, which is the type 1 regulatory subunit of PKA or mutations in phosphodiesterase 4 (PDE4D), both causing an impaired PKA activation [52,53]. Furthermore, inactivating mutations in the maternal allele of GNAS gene, coding for the binding protein Gαs, cause Pseudohypoparathyroidism type IA, also known as Albright hereditary osteodystrophy (AHO) [54,55]. This disease is characterized by short stature, subcutaneous ossifications and brachydactyly, and is associated with PTH resistance. If the same mutations are inherited from the father, the AHO phenotype occurs without hormone resistance [56]. It has been proposed that the defective Gαs-mediated hypertrophy inhibition could result in promotion of the Gαq-mediated chondrocytes’ hypertrophy, leading to premature growth plate closure and favoring short stature.
On the other hand, McCune-Albright syndrome or isolated fibrous dysplasia (FD) of bone is caused by gain-of-function mutations in distinct sites of the GNAS gene compared to AHO [57,58]. These mutations cause overproduction of cAMP in a ligand-independent manner in osteogenic cells. This leads to the accelerated production of bone marrow stromal cells, while inhibiting the differentiation of these progenitors into mature osteoblasts [59]. These immature cells lead to under-mineralized bone with disrupted micro-architecture. Finally, deletions of the chromosomal region 2q37, which include the HDAC4 gene, cause brachydactyly–mental retardation syndrome characterized by brachydactyly type E, craniofacial abnormalities and intellectual disabilities [60].

4. Wingless and Int-1

WNT is a complex regulator of skeletal development. Until now, three different WNT pathways have been identified: one canonical pathway, the WNT/β-catenin, and two non-canonical pathways, the WNT/planar cell polarity (PCP) and the WNT/Ca2+. All these signaling pathways are activated by the binding of extracellular WNT ligands to one of the seven-pass transmembrane Frizzled (FZD) receptors. Depending on the pathway, the activation occurs with or without specific co-receptors like lipoprotein-related protein (LRP) or receptor tyrosine kinase-like orphan receptors (ROR) [61,62]. In the canonical pathway, WNT ligands bind the receptor complex formed by LRP5/6 and FZD. This activation causes the translocation of β-catenin in the nucleus where it activates WNT target genes controlling proliferation and differentiation. When WNT is absent, β-catenin is bound in a complex composed by glycogen synthase kinase 3β (GSK3β), axin and adenomatosis polyposis coli (APC) and degraded by proteasome. In the non-canonical PCP pathway, Jun kinase (JNK) is activated via disheveled (DVL) and the RAC and Rho small GTPases. Finally, in the non-canonical WNT/Ca2+ pathway, WNT binds to FZD receptors and ROR causing the intracellular Ca2+ release and the activation of some calcium-sensitive enzymes. More downstream, this event activates the nuclear factor of activated T cells (NF-AT), which translocates to the nucleus and induces specific gene expressions. WNT signaling pathways play a central role in bone development regulating chondrocyte and osteoblast differentiation (Figure 2A).
WNTs secreted by the ectoderm act via a β-catenin-dependent pathway. It blocks the cartilage formation in limb bud mesenchymal cells, by inhibiting SOX9 expression through a repressive chromatin mark (H3K27me3) and DNA methylation over the SOX9 promoter [63]. The inactivation of β-catenin causes an increase of SOX9 expression, leading to a decreased chondrocyte proliferation and a delayed hypertrophic maturation. In addition, the PCP pathway plays a unique role in inducing chondrocyte column formation in the growth plate [64,65]. WNT can also promote chondrocyte hypertrophy by inhibiting PTHrP activity [43]. Some members of the WNT family, such as WNT5A and WNT5B, regulate the transition of chondrocytes to hypertrophy in the growth plate. It has been shown, that the absence of WNT5A delays chondrocyte hypertrophy and that a proper level of WNT5A/B signaling is required for the normal transition of chondrocytes to hypertrophy [66,67]. Some WNT proteins inhibit chondrogenesis from mesenchymal stem cells (MSC), favoring osteoblastogenesis. WNT has a primary role in osteoblast differentiation, since the activation of the β-catenin pathway is essential to allow the differentiation of mesenchymal progenitors in mature osteoblasts. Several studies confirm that WNT activation and inhibition correspond to the increase and the decrease of the bone mass, respectively [68,69,70,71].
WNT ligands consist of 19 different cysteine-reach secreted glycoproteins. Several of them have been associated with SD. For example, loss-of-function mutations in WNT1, involved in the canonical pathway, are responsible for osteogenesis imperfecta (OI) type XV and for early onset osteoporosis [72]. Loss-of-function of WNT3, playing an essential role in axis formation and limb growth, causes tetra-melia syndrome type 1, consisting on the absence of all four limbs [73]. The WNT5A gene, involved in the WNT/PCP non canonical pathway, is linked to the autosomal dominant form of Robinow syndrome (RS) type 1 [74]. Mutations in WNT6 have been identified in acro-pectoro-vertebral dysplasia (F-syndrome) and mutations in WNT7A gene, involved in limb development and contributing to anteroposterior patterning, have been identified Al-Awadi-Raas-Rothscild syndrome and Fuhrmann syndrome. Finally, mutations in the WNT10B gene, a key regulator of osteogenesis, playing an important role in the development of hands and feet, cause split-hand/foot malformation type 6 [75,76,77,78]. Mutations have been also identified in WNT receptors and co-receptors: with FZD2, being associated with omodysplasia type 2; ROR2 with autosomal dominant brachydactyly type 1, or autosomal recessive RS type 1; and LRP4 with sclerostosis type 2 and Cenani-Lenz syndrome. Interestingly, mutations in the co-receptor LRP5 result in opposite bone mass phenotype. Loss-of-function mutations in LRP5 lead to decreased binding of WNT ligands and decreased WNT signaling activity causing osteoporosis. In contrast, other specific mutations in LRP5 affecting the binding of Dickkopf-1, an inhibitor of WNT signaling, result in gain-of-function of LRP5 and in osteosclerosis [79,80,81,82,83,84,85,86,87,88]. Extracellular WNT inhibitors and activators play also a significant role in bone homeostasis and development. This is demonstrated by the identification of mutations in the WNT inhibitor SOST disrupting the ability of SOST to link with LRP co-receptors. This generates an increased WNT signaling and an increased bone mass like in sclerosteosis type 1, Van Buchem diseases and craniodiaphyseal dysplasia. Furthermore, Cenani-Lenz-like non-syndromic bilateral oligosyndactyly and Pyle disease have been associated with mutations in the WNT inhibitors GREM1 and SFRP4 respectively. Loss-of-function mutations in AMER1 (or WTX), an intracellular inhibitor of WNT are responsible for X-linked osteopathia striata with cranial sclerosis [89]. Finally, Keipert syndrome and tetra-amelia syndrome are caused by loss-of-function mutations in the WNT activators GPC6 and RSPO2, respectively [78].
The discovery and the understanding of all these diseases showed how WNT signaling is essential to regulate bone density in humans, since its hyperactivation causes skeletal diseases characterized by high-bone mass phenotype, while its inhibition causes decreased bone formation. Furthermore, it explains why WNT is used as therapeutic target to improve bone mass in patients affected by skeletal diseases such as osteoporosis or osteogenesis imperfecta.

5. Notch

Similar to WNT/β-catenin signaling, Notch signaling also suppresses chondrogenesis through four NOTCH receptors (NOTCH1-4) and at least five ligands (two members of the Jagged family: Jag1 and Jag2 and three members of the Delta-like family: Dll1, Dll3, and Dll4) [90]. In the canonical Notch pathway, the ligands bind to the NOTCH receptors present on the adjacent cell surface. This triggers one first proteolytic cleavage generating a Notch Extracellular Truncation (NEXT) and a consequent proteolytic cleavage mediated by the γ-secretase complex, composed by Presenilin 1 and 2. This cleavage results in the release of the Notch Intracellular Domain (NICD) in the cytoplasm [91,92]. NICD translocates into the nucleus where it forms a complex with the transcription factor CSL (C promoter-binding factor 1, Suppressor of Hirless and Lag1), also known as RBPJk, and the transcriptional coactivator Mastermind-like 1 (MAML1). This ternary complex activates the expression of transcription factors of the families Hairy Enhancer of Split (HES 1, 4, 5, 6 and 7) and Hes related with YRPW motif (HEY 1, 2 and L) [93]. Multiple NOTCH ligands and receptors are expressed in the prechondrogenic mesenchyme and inhibit both mesenchymal condensation and subsequent chondrocyte differentiation (Figure 2B) [94,95]. This occurs when Hey and Hes transcription factors are activated and bind to SOX9 enhancer and suppress the SOX9 gene expression, which is essential for chondrocyte differentiation [96,97].
Notch signaling is also critical for axial skeleton segmentation during somitogenesis [98,99]. Defective somitogenesis, due to abnormal Notch signaling, cause Spondylocostal dysostosis and vertebral segmentation defect characterized by vertebrae and ribs anomalies with consequent trunk dwarfism [100,101]. These pathologies have been associated with mutations in different components of Notch signaling, such as DLL3, HES7, Mesoderm Posterior (MESP) 2, a Notch target gene, and Lunatic Fringe (LFNG), a member of the Fringe family, involved in the post-translational modifications of NOTCH receptors [102,103,104,105].
In parallel, Notch signaling acts upstream of RUNX and regulates the osteochondro-progenitor cell proliferation and lineage specification [106]. Depending on the osteoblast differentiation stage, Notch signaling can promote or inhibit the process [107]. In the early stage of osteoblastogenesis, the Hey transcriptional factors, downstream of RBPjK, inhibit the Runx2 expression and, in consequence, prevent the differentiation of osteochondroprogenitor cells into perichondral cells [108,109]. Meanwhile, during the intermediate stage, the expression of NCID promotes proliferation and the differentiation of perichondral cells into preosteoblasts. Finally, in the late stage, Notch inhibits the preosteoblast differentiation in mature osteoblasts [110]. To resume, Notch signaling inhibits the early and late stage of osteoblastogenesis but promotes the intermediate stage. Consistent with this description, gain-of-function mutations in NOTCH2, the major receptor involved in the chondrocyte and osteoblast differentiation, are responsible for Hadju–Cheney syndrome, a disorder characterized by focal bone lysis of distal phalanges, progressive bone loss and fractures [111,112]. Loss-of-function mutations in NOTCH1, RBPJ and DLL4 are responsible for Adams Oliver syndrome, a congenital condition characterized by aplasia cutis congenita of the scalp and transverse limb defects [113,114].
Since the Notch pathway can have different roles depending on the cell differentiation stage, it could be very difficult to target this pathway for therapies.

6. Transforming Growth Factor-Beta and Bone Morphogenetic Protein

The TGF-β superfamily is a group of more than 40 members including 3 TGF-β proteins (TGF-β1, TGF-β2 and TGF-β3), and 14 BMPs, Activins and Growth and Differentiation Factors (GDFs) [115]. It is involved in two principal pathways, TGF-β and BMP signaling. In both cases, the binding of the TGF-β superfamily ligands to a heteromeric serine/threonine receptor ligand complex formed by two type I (TGFBRI, BMPRI or ALK) and two type II receptors (TGFBR2 or BMPR2) causes the autophosphorylation of type II receptors. This in turn phosphorylate type I receptors and the regulatory Smad transcription factors (R-SMADS). These R-SMADS form a complex with the coregulatory Smad (Co-SMAD), SMAD4, which accumulates in the nucleus and regulates gene transcription [116,117]. TGF-β signaling mostly involves SMAD 2 and 3 proteins, whereas BMP signaling is principally mediated by SMAD 1, 5, and 8. As an alternative to the SMAD-mediated canonical pathways, TGF-β and BMP also activate p38 MAPK family cascade through non-canonical pathways. TGF-β, BMPs and their receptors play a relevant role in all stages of bone development (Figure 3A,B).
This has been demonstrated by studying several conditional knockout mouse models for TGF-β, its receptors and SMAD proteins. All these models are characterized by an impairment of endochondral and intramembranous bone formation [118].
During chondrogenesis, BMP and TGF-β signaling are required for the expression and maintenance of SOX9 and, in consequence, for the formation of chondrogenic mesenchymal condensations. TGF-β, BMPs and their receptors are also expressed in proliferating chondrocytes and hypertrophic chondrocytes and regulate chondrocyte proliferation and differentiation. In particular, TGF-β promotes the condensation and differentiation of mesenchymal cells, induces chondrocyte proliferation, but inhibits terminal chondrocyte differentiation [119,120]. On the contrary, BMP signaling is not essential for the mesenchymal condensation, but is indispensable for mesenchymal cell differentiation and for chondrocyte proliferation and maturation [121,122].
In osteoblastogenesis, TGF-β promotes expansion and proliferation of osteoprogenitors, early differentiation and commitment to the osteoblastic lineage through the MAPKs and SMAD 2/3 pathways. Conversely, it prevents the terminal osteoblast differentiation [123]. Activating mutations in the genes coding for the ligand TGF-β2 and 3, for the TGF-β receptors (TGFBR1 or TGFBR2), and for the intracellular SMAD2 and 3 have all been associated with the Loeys-Dietz syndrome, an autosomal dominant condition characterized by skeletal deformities and bone overgrowth [124]. Mutations in the gene coding for the ligand TGF-β1 and causing the hyperactivation of the TGF-β signaling are responsible for the Camurati-Engelmann disease, characterized by increased bone density [125,126].
Focusing on BMP signaling, genetic studies have shown that several BMPs, such as BMP-2, 4, 5, 6 and 7 have strong osteogenic capacity [127]. In particular, BMP-2, with the coordinated help of BMP-4, controls the transition from RUNX2- to OSX- positive osteoblasts. On the other hand, BMP-7 promotes the expression of osteoblast differentiation markers as ALP activity and enhances calcium mineralization. Its absence in postnatal bones can be compensated by the others BMPs. Instead, BMP-3 inhibits skeletal progenitor cell differentiation to mature osteoblasts and regulates adult bone mass [118].
In humans, activating mutations in one of the Type I receptors, the Activin receptor IA/Activin-Like kinase 2 (ACVR1/ALK2), cause Fibrodysplasia ossificans progressive (FOP), a rare disease characterized by heterotopic endochondral ossification, through an increased BMP Smad-dependent and non-canonical p38 MAPK signaling activity [128]. Mutations in BMPR1 (or ALK6), which is specifically expressed during chondrogenesis and osteoblastic differentiation, cause brachydactyly type A2 and acromesomelic dysplasia. Both diseases have been also associated with loss-of-function mutations in GDF5 [129]. Patients with these diseases have normal axial skeletons but missing or fused distal elements in hands and feet. These discoveries highlighted the importance of BMP signaling in distal limb patterning. Disruptions of the BMP pathway also causes abnormal axial skeletal patterning. GDF6, a close relative to GDF5, is associated with Klippel-Feil syndrome causing bone fusions [130]. Gain-of-function mutations in SMAD4, the only common SMAD for both TGF-β and BMP signaling, results in Myhre syndrome, characterized by short stature, facial dysmorphism, stiff joints and brachydactyly [131].
The TGF-β/BMP signaling is also negatively regulated by several mechanisms: intracellular antagonists, like SMAD 6 and 7; the inner nuclear membrane protein LEMD3 and the SKI protein influencing the SMAD signaling; extracellular ligand antagonists, like NOGGIN and BMPER; intracellular ubiquitin ligases and transcriptional repressors. Over-expression of NOGGIN causes osteopenia, fractures and multiple synostoses syndrome, consisting of facial dysmorphism, craniosynostosis and multiple joint fusion [132]. Heterozygous missense mutations in the antagonist NOGGIN, leading to an increased inhibitory activity, also result in brachydactyly type B [133]. Mutations in BMPER cause diaphanospondylodysostosis characterized by craniofacial anomalies and vertebral segmentation [134]. Moreover, loss-of-function mutations in the LEMD3 gene are associated with osteopoikilosis with and without melorheostosis, characterized by multiple round foci of increased bone density and hyperostosis respectively [135]. Finally, loss-of-function mutations in the SKI protein, which inhibits SMAD2/3 activation, are responsible for Shprintzen Goldberg Syndrome, characterized by marfanoid habitus and craniosynostosis [136].
As mentioned in this paragraph, numerous human SD are related to TGF-β/BMP signaling pathways confirming their essential role in bone development. In particular, it seems that increased TGF-β signaling can result in either increased bone formation or craniosynostosis. Indeed, the clinical consequences depend on tissue-specificity expression of the mutant allele and on the interaction with other signaling pathways. On the other hand, impaired BMP signaling mostly causes distal and axial skeletal defects, demonstrating a prominent role of BMP in chondrocyte differentiation and establishment of joint boundaries.

7. Fibroblast Growth Factor

Fibroblast growth factors (FGFs) are a large family of 18 or more proteins which mostly bind to four cell surface tyrosine kinase FGF receptors (FGFR 1-4). This binding induces the dimerization of the receptor tyrosine kinase domains and their sequential trans-phosphorylation [137]. Consequently, it promotes the phosphorylation of the adaptor proteins FGFR substrate 2α (FRS2α) and the recruitment of other adaptor proteins like signal transducer and activation of transcription1 (STAT1), phospholipase γ (PLCγ) and the guanine nucleotide exchange factor GRB2. These proteins activate multiple signaling pathways, including JAK-STAT, proteinase kinase C (PKC), mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K), [138].
FGFs and their receptors are expressed during all stages of the bone development in a time- and space-dependent manner. For example, FGFR1 is expressed during mesenchymal condensation, in perichondrium and periosteum and in hypertrophic chondrocytes of the growth plate [139]. FGFR2 is initially expressed at high levels in condensed mesenchyme and then in perichondrium and periosteum [140]. FGFR3 is expressed in proliferative chondrocytes in the growth plate and, when it binds to its ligands FGF9 or FGF18, it promotes chondrocyte proliferation and the initial chondrocyte hypertrophy during the early stages of development [141,142]. On the contrary, it inhibits chondrocyte proliferation and hypertrophy in the later stages of development (Figure 3C) [143,144,145].
FGF signaling is fundamental also in intramembranous ossification and in the regulation of all steps of osteoblastogenesis. In particular, FGFR1 is expressed in calvaria mesenchyme and later in osteoblasts. During early development, it promotes osteoblast differentiation without affecting RUNX2 expression, while, in mature osteoblasts, it inhibits their mineralization activity [139]. In contrast, FGFR2, expressed in differentiating osteoblasts, promotes the proliferation of preosteoblasts and the anabolic function of mature osteoblasts mostly by up-regulating RUNX2 expression [146,147]. Finally, mice lacking Fgfr3 showed an increase in osteoblast number but a decrease in osteoid mineralization [148].
Mutations in FGFRs cause human skeletal dysplasia with a variable degree of severity. The most common genetic skeletal dysplasia in humans is achondroplasia, a rhizomelic short limb dwarfism characterized by short stature, limited elbow extension and frontal bossing. It is caused by gain-of-function mutations in the FGFR3 gene leading to an overactivation of the FGF signaling [149,150,151]. Since in the growth plate FGFR3 is predominantly expressed in proliferating and prehypertrophic chondrocytes, these mutations cause a reduced chondrocyte proliferation and an impaired hypertrophic differentiation [152,153,154]. Related chondrodysplasia syndromes include the milder form of dwarfism, hypochondroplasia, characterized by short stature and increased head circumference [155,156,157], the more severe and lethal forms, thanathophoric dysplasia type I and II, and the severe achondroplasia with developmental delay and acantosis nigricans (SADDAN) [158,159]. All these syndromes are caused by gain-of-function mutations in different domains of the FGFR3 protein and the phenotype severity is linked to the degree of FGFR3 activation [153]. On the contrary, inactivation of FGFR3 cause skeletal overgrowth, campodactyly, tall stature and hearing loss (CATSHL) syndrome [160,161] and Lacrimoauriculodentodigital (LADD) syndrome. This last disorder is characterized by micrognatia and variable digit defects, and has been also associated with mutations in FGFR2 [162]. The role of FGFR3 in intramembranous ossification is highlighted by the identification of FGFR3 mutations in craniosynostosis disorders like Crouzon syndrome with acanthosis nigricans and Muenke syndrome [163,164]. Craniosynostosis, characterized by premature fusion of cranial sutures due to increased osteoblast proliferation or differentiation, or to increased mineralizing functions of osteoblasts, are also caused by mutations in FGFR1 and FGFR2. Crouzon, Apert, Beare-Stevenson with cutis gyrata, Bent-bone dysplasia, Saethre-Choetzen, Jackson-Weiss and Pfeiffer syndromes are all caused by activating mutation in FGFR2 gene and the consequent accelerated osteoblast maturation in the sutures [165,166,167]. Jackson-Weiss and Pfeiffer syndrome have also been associated with mutation in FGFR1, like the Hartsfield syndrome and the osteoglophonic dysplasia [168,169,170,171]. Finally, mutations in genes encoding FGF ligands have also been identified in SD, like FGF9 in multiple synostosis syndrome type 3, FGF10 in LADD and FGF23 in hypophosphatemic rickets [172,173,174]. In this last disorder, FGF23 overexpression causes defects in osteocytes and abnormal kidney function. This demonstrates that signaling defects can be tissue and organ nonautonomous [175].
During bone development, the FGF signaling can be modulated by C-type natriuretic peptide (CNP) action. When CNP binds to its NPR-B receptor, the MAPK signaling activated by FGFR3 is inhibited (Figure 3C). Similarly, the binding of FGF2 and FGF18 ligands to FGFR reduces CNP action [176,177]. CNP is expressed in proliferating and pre-hypertrophic chondrocytes and promotes chondrocyte proliferation and differentiation. Dominant negative and gain-of-function mutations in NPR2, the gene encoding NPR-B, are responsible for short and tall stature phenotype, such as in acromesomelic dysplasia type Maroteaux and tall stature with long halluces type NPR2, respectively [178,179]. These studies suggest that CNP signaling promotes chondrocytes proliferation during bone development and that it acts as a negative cross talk between FGF and MAPK. For this reason, recombinant analogues of CNP are used as promising therapy for achondroplasia.

8. Transcription Factors

8.1. SOX9

SOX9 is a transcription factor of the SRY family that regulates sex determination and developmental events like cartilage development. SOX9 is the earliest nuclear factor required for chondrogenesis. It is initially expressed in mesenchymal condensations of the early skeletal precursors. It is dispensable for the initial mesenchymal condensation, but crucial for the subsequent chondrocyte differentiation. In fact, in its absence, chondrogenesis is blocked. In the growth plate, SOX9 is expressed at highest levels in proliferating and prehypertrophic chondrocytes and less expressed in chondrocytes undergoing hypertrophy [2,180]. SOX9 directly activates chondrocyte differentiation markers like collagen type II. It also induces the expression of SOX5 and SOX6 working with SOX9 to activate the chondrocyte differentiation [181]. In addition, SOX9 expression sustains chondrocyte survival through PI3K-AKT pathway and maintains proliferation of columnar chondrocytes. It also prevents the entering of columnar chondrocytes in the prehypertrophic stage and promotes the subsequent hypertrophy [182]. SOX9 represses the initial chondrocyte maturation through the interaction with β-catenin and its consequential disruptions. This leads to the inhibition of the WNT pathway, a promoter of chondrocyte hypertrophy [183,184]. SOX9 can also directly interact and block the activity of RUNX2 (discussed below), one of the main transcription factors involved in chondrocyte maturation and osteoblastogenesis. Finally, SOX9 regulates the gene expression of specific markers for hypertrophic chondrocytes, like collagen type X and Vegfa [182,185,186,187]. SOX9 plays an important role in the developing axial skeleton and maintains the notochord and the demarcation of intervertebral disc compartments. Heterozygous loss-of-function mutations in SOX9 gene have been associated with campomelic dysplasia, an autosomal dominant skeletal dysplasia characterized by hypoplastic scapulae, progressive disc degeneration, small chest, short long bones with bowing of the lower extremities, Pierre Robin sequence and sex reversal in males [188,189,190].

8.2. RUNX2

RUNX2 is a transcription factor belonging to the RUNX family composed by RUNX1, RUNX2 and RUNX3 [191]. RUNX2 is essential for both intramembranous ossification and endochondral ossification during skeletogenesis. It is involved principally in chondrocyte and osteoblast differentiation and in the regulation of extracellular matrix protein expression during these processes. It is initially expressed within the chondrogenic mesenchyme, subsequent to and dependent on SOX9 expression [192]. During endochondral bone development, RUNX2 is weakly expressed in proliferative chondrocytes and highly expressed in prehypertrophic chondrocytes until terminal hypertrophic chondrocytes and in perichondrium [193,194]. It regulates chondrocyte hypertrophy by driving the expression of collagen type X in hypertrophic chondrocytes, of matrix metallopeptidase 13 (MMP13) in terminal hypertrophic chondrocytes and also by interacting with BMP-regulated SMADs [195,196,197,198]. Moreover, RUNX2 controls chondrocyte maturation, enhancing FGF18 expression in the perichondrium [199]. In endochondral and intramembranous bones, RUNX2 is strongly detected in osteoblast progenitors, immature and early mature osteoblasts. It is required for osteoblast progenitor proliferation, their differentiation into osteoblasts, and for the proper function of the mature osteoblasts [200,201,202]. Haploinsufficiency of RUNX2 causes cleidocranial dysplasia, characterized by short stature, delayed closure of fontanelles, prominent forehead, drooping shoulders and abnormal dental development. The distinctive radiological features are shortened or absent clavicles, delayed ossification of the skull bones, and delayed ossification of pelvic bones [203,204]. On the other hand, duplications of the RUNX2 gene are associated with metaphyseal dysplasia with maxillary hypoplasia, characterized by metaphyseal flaring of long bones, enlargement of the medial halves of the clavicles, maxillary hypoplasia, and dystrophic teeth [205,206].

8.3. OSX

OSX, a transcription factor containing three C2H2-type zinc fingers, controls the genetic program of osteoblast differentiation and bone formation. Expression of OSX in osteoblast precursors induces the differentiation of these cells into mature and functional osteoblasts and, then, into osteocytes [207,208]. OSX can also be a negative regulator of chondrocyte differentiation. In fact, when OSX is expressed in RUNX2-positive cells, the expression of SOX9 is down-regulated and the cells exist as osteoblast precursors. Then RUNX2/OSX-positive cells differentiate into mature osteoblasts, in which SOX9 is not expressed. This means that without the expression of OSX, the RUNX2-positive precursors do not progress into the preosteoblast stage but, instead, they remain in the chondrogenic stage [209]. OSX also plays an important role in extracellular matrix calcification by activating MMP13 expression in hypertrophic chondrocytes [210]. A homozygous mutation in the OSX gene has been identified in a patient with a moderate form of osteogenesis imperfecta, presenting with bone fractures, mild bone deformities and delayed tooth eruption. This confirms the importance of a proper OSX expression for bone health [211].

9. Conclusions

In this review, we discussed the main signaling pathways involved in bone development and how mutations in their components have been associated with SD. It is important to highlight that even if the signaling pathways have been discussed independently, there is a complex cross-talk among them at multiple levels. This, in association with the evidence that the mutation consequences depend on the specificity of the mutations and on their temporal and spatial mode of action, makes more difficult the understanding of the physiopathological mechanisms of these diseases. Moreover, these signaling pathways can be secondarily affected by alterations in other cellular processes, such as extracellular matrix regulation or metabolic processing. Indeed, several skeletal dysplasia, that we decided to omit in this review, have been associated with mutations in these processes. Fortunately, in the last decade, the development of new technologies, like whole exome and genome sequencing has accelerated the identification of skeletal dysplasia-causing mutations. On the other hand, the development of CRISPR-Cas9 technology and of several mouse models is helping the deciphering of the physiopathological mechanisms. Advanced genetic testing is also helping the diagnosis of skeletal dysplasia. The diagnosis and management of these pathologies have long been based on clinical feature and skeletal imaging. Today, these key techniques are increasingly combined with the genetic testing in order to obtain a more accurate and early diagnosis of SD. It also aids in prognosis and in counselling families regarding genetic recurrence risk and preconceptional reproductive planning [212,213,214]. These continuous discoveries will help to expand the genotype–phenotype correlation of SD and to develop new therapeutic strategies. Nowadays, few treatments are available for SD, but several clinical trials are ongoing to validate new drugs targeting specifically these pathways in achondroplasia or FOP for example, and highlighting the importance of multidisciplinary cross talks (from bed to bench side) [215].

Author Contributions

A.G. and V.C.-D. have both contributed to the writing of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Opperman, L.A. Cranial Sutures as Intramembranous Bone Growth Sites. Dev. Dyn. 2000, 219, 472–485. [Google Scholar] [CrossRef]
  2. Kozhemyakina, E.; Lassar, A.B.; Zelzer, E. A Pathway to Bone: Signaling Molecules and Transcription Factors Involved in Chondrocyte Development and Maturation. Development 2015, 142, 817–831. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Long, F.; Ornitz, D.M. Development of the Endochondral Skeleton. Cold Spring Harb. Perspect. Biol. 2013, 5, a008334. [Google Scholar] [CrossRef] [Green Version]
  4. Mortier, G.R.; Cohn, D.H.; Cormier-Daire, V.; Hall, C.; Krakow, D.; Mundlos, S.; Nishimura, G.; Robertson, S.; Sangiorgi, L.; Savarirayan, R.; et al. Nosology and Classification of Genetic Skeletal Disorders: 2019 Revision. Am. J. Med. Genet. 2019, 179, 2393–2419. [Google Scholar] [CrossRef]
  5. Ingham, P.W. Hedgehog Signaling in Animal Development: Paradigms and Principles. Genes Dev. 2001, 15, 3059–3087. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Briscoe, J.; Thérond, P.P. The Mechanisms of Hedgehog Signalling and Its Roles in Development and Disease. Nat. Rev. Mol. Cell. Biol. 2013, 14, 416–429. [Google Scholar] [CrossRef]
  7. Pan, A.; Chang, L.; Nguyen, A.; James, A.W. A Review of Hedgehog Signaling in Cranial Bone Development. Front. Physiol. 2013, 4, 61. [Google Scholar] [CrossRef] [Green Version]
  8. Chiang, C.; Litingtung, Y.; Lee, E.; Young, K.E.; Corden, J.L.; Westphal, H.; Beachy, P.A. Cyclopia and Defective Axial Patterning in Mice Lacking Sonic Hedgehog Gene Function. Nature 1996, 383, 407–413. [Google Scholar] [CrossRef] [PubMed]
  9. Fan, C.M.; Porter, J.A.; Chiang, C.; Chang, D.T.; Beachy, P.A.; Tessier-Lavigne, M. Long-Range Sclerotome Induction by Sonic Hedgehog: Direct Role of the Amino-Terminal Cleavage Product and Modulation by the Cyclic AMP Signaling Pathway. Cell 1995, 81, 457–465. [Google Scholar] [CrossRef] [Green Version]
  10. Hu, D. A Zone of Frontonasal Ectoderm Regulates Patterning and Growth in the Face. Development 2003, 130, 1749–1758. [Google Scholar] [CrossRef] [Green Version]
  11. Jeong, J.; Mao, J.; Tenzen, T.; Kottmann, A.H.; McMahon, A.P. Hedgehog Signaling in the Neural Crest Cells Regulates the Patterning and Growth of Facial Primordia. Genes Dev. 2004, 18, 937–951. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Riddle, R.D.; Johnson, R.L.; Laufer, E.; Tabin, C. Sonic Hedgehog Mediates the Polarizing Activity of the ZPA. Cell 1993, 75, 1401–1416. [Google Scholar] [CrossRef]
  13. Karp, S.J.; Schipani, E.; St-Jacques, B.; Hunzelman, J.; Kronenberg, H.; McMahon, A.P. Indian Hedgehog Coordinates Endochondral Bone Growth and Morphogenesis via Parathyroid Hormone Related-Protein-Dependent and -Independent Pathways. Development 2000, 127, 543–548. [Google Scholar]
  14. Kobayashi, T.; Chung, U.-I.; Schipani, E.; Starbuck, M.; Karsenty, G.; Katagiri, T.; Goad, D.L.; Lanske, B.; Kronenberg, H.M. PTHrP and Indian Hedgehog Control Differentiation of Growth Plate Chondrocytes at Multiple Steps. Development 2002, 129, 2977–2986. [Google Scholar] [PubMed]
  15. Lanske, B.; Karaplis, A.C.; Lee, K.; Luz, A.; Vortkamp, A.; Pirro, A.; Karperien, M.; Defize, L.H.; Ho, C.; Mulligan, R.C.; et al. PTH/PTHrP Receptor in Early Development and Indian Hedgehog-Regulated Bone Growth. Science 1996, 273, 663–666. [Google Scholar] [CrossRef]
  16. Minina, E.; Wenzel, H.M.; Kreschel, C.; Karp, S.; Gaffield, W.; McMahon, A.P.; Vortkamp, A. BMP and Ihh/PTHrP Signaling Interact to Coordinate Chondrocyte Proliferation and Differentiation. Development 2001, 128, 4523–4534. [Google Scholar]
  17. Vortkamp, A.; Lee, K.; Lanske, B.; Segre, G.V.; Kronenberg, H.M.; Tabin, C.J. Regulation of Rate of Cartilage Differentiation by Indian Hedgehog and PTH-Related Protein. Science 1996, 273, 613–622. [Google Scholar] [CrossRef]
  18. Kobayashi, T.; Soegiarto, D.W.; Yang, Y.; Lanske, B.; Schipani, E.; McMahon, A.P.; Kronenberg, H.M. Indian Hedgehog Stimulates Periarticular Chondrocyte Differentiation to Regulate Growth Plate Length Independently of PTHrP. J. Clin. Investig. 2005, 115, 1734–1742. [Google Scholar] [CrossRef]
  19. St-Jacques, B.; Hammerschmidt, M.; McMahon, A.P. Indian Hedgehog Signaling Regulates Proliferation and Differentiation of Chondrocytes and Is Essential for Bone Formation. Genes Dev. 1999, 13, 2072–2086. [Google Scholar] [CrossRef] [Green Version]
  20. Hilton, M.J.; Tu, X.; Cook, J.; Hu, H.; Long, F. Ihh Controls Cartilage Development by Antagonizing Gli3, but Requires Additional Effectors to Regulate Osteoblast and Vascular Development. Development 2005, 132, 4339–4351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Long, F.; Chung, U.; Ohba, S.; McMahon, J.; Kronenberg, H.M.; McMahon, A.P. Ihh Signaling Is Directly Required for the Osteoblast Lineage in the Endochondral Skeleton. Development 2004, 131, 1309–1318. [Google Scholar] [CrossRef] [Green Version]
  22. Radhakrishna, U.; Wild, A.; Grzeschik, K.H.; Antonarakis, S.E. Mutation in GLI3 in Postaxial Polydactyly Type A. Nat. Genet. 1997, 17, 269–271. [Google Scholar] [CrossRef]
  23. Hui, C.C.; Joyner, A.L. A Mouse Model of Greig Cephalopolysyndactyly Syndrome: The Extra-ToesJ Mutation Contains an Intragenic Deletion of the Gli3 Gene. Nat. Genet. 1993, 3, 241–246. [Google Scholar] [CrossRef] [PubMed]
  24. Vortkamp, A.; Gessler, M.; Grzeschik, K.H. GLI3 Zinc-Finger Gene Interrupted by Translocations in Greig Syndrome Families. Nature 1991, 352, 539–540. [Google Scholar] [CrossRef] [Green Version]
  25. Kang, S.; Graham, J.M.; Olney, A.H.; Biesecker, L.G. GLI3 Frameshift Mutations Cause Autosomal Dominant Pallister-Hall Syndrome. Nat. Genet. 1997, 15, 266–268. [Google Scholar] [CrossRef] [PubMed]
  26. Fujioka, H.; Ariga, T.; Horiuchi, K.; Otsu, M.; Igawa, H.; Kawashima, K.; Yamamoto, Y.; Sugihara, T.; Sakiyama, Y. Molecular Analysis of Non-Syndromic Preaxial Polydactyly: Preaxial Polydactyly Type-IV and Preaxial Polydactyly Type-I. Clin. Genet. 2005, 67, 429–433. [Google Scholar] [CrossRef]
  27. Gao, B.; Guo, J.; She, C.; Shu, A.; Yang, M.; Tan, Z.; Yang, X.; Guo, S.; Feng, G.; He, L. Mutations in IHH, Encoding Indian Hedgehog, Cause Brachydactyly Type A-1. Nat. Genet. 2001, 28, 386–388. [Google Scholar] [CrossRef]
  28. Klopocki, E.; Lohan, S.; Brancati, F.; Koll, R.; Brehm, A.; Seemann, P.; Dathe, K.; Stricker, S.; Hecht, J.; Bosse, K.; et al. Copy-Number Variations Involving the IHH Locus Are Associated with Syndactyly and Craniosynostosis. Am. J. Hum. Genet. 2011, 88, 70–75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Bosse, K.; Betz, R.C.; Lee, Y.A.; Wienker, T.F.; Reis, A.; Kleen, H.; Propping, P.; Cichon, S.; Nöthen, M.M. Localization of a Gene for Syndactyly Type 1 to Chromosome 2q34-Q36. Am. J. Hum. Genet. 2000, 67, 492–497. [Google Scholar] [CrossRef] [Green Version]
  30. Hellemans, J.; Coucke, P.J.; Giedion, A.; De Paepe, A.; Kramer, P.; Beemer, F.; Mortier, G.R. Homozygous Mutations in IHH Cause Acrocapitofemoral Dysplasia, an Autosomal Recessive Disorder with Cone-Shaped Epiphyses in Hands and Hips. Am. J. Hum. Genet. 2003, 72, 1040–1046. [Google Scholar] [CrossRef] [Green Version]
  31. Escamilla, M.A.; DeMille, M.C.; Benavides, E.; Roche, E.; Almasy, L.; Pittman, S.; Hauser, J.; Lew, D.F.; Freimer, N.B.; Whittle, M.R. A Minimalist Approach to Gene Mapping: Locating the Gene for Acheiropodia, by Homozygosity Analysis. Am. J. Hum. Genet. 2000, 66, 1995–2000. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Umair, M.; Ahmad, F.; Bilal, M.; Ahmad, W.; Alfadhel, M. Clinical Genetics of Polydactyly: An Updated Review. Front. Genet. 2018, 9, 447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Lohan, S.; Spielmann, M.; Doelken, S.C.; Flöttmann, R.; Muhammad, F.; Baig, S.M.; Wajid, M.; Hülsemann, W.; Habenicht, R.; Kjaer, K.W.; et al. Microduplications Encompassing the Sonic Hedgehog Limb Enhancer ZRS Are Associated with Haas-Type Polysyndactyly and Laurin-Sandrow Syndrome. Clin. Genet. 2014, 86, 318–325. [Google Scholar] [CrossRef] [PubMed]
  34. Lee, K.; Lanske, B.; Karaplis, A.C.; Deeds, J.D.; Kohno, H.; Nissenson, R.A.; Kronenberg, H.M.; Segre, G.V. Parathyroid Hormone-Related Peptide Delays Terminal Differentiation of Chondrocytes during Endochondral Bone Development. Endocrinology 1996, 137, 5109–5118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Gardella, T.J.; Jüppner, H. Molecular Properties of the PTH/PTHrP Receptor. Trends. Endocrinol. Metab. 2001, 12, 210–217. [Google Scholar] [CrossRef]
  36. Bringhurst, F.R.; Juppner, H.; Guo, J.; Urena, P.; Potts, J.T.; Kronenberg, H.M.; Abou-Samra, A.B.; Segre, G.V. Cloned, Stably Expressed Parathyroid Hormone (PTH)/PTH-Related Peptide Receptors Activate Multiple Messenger Signals and Biological Responses in LLC-PK1 Kidney Cells. Endocrinology 1993, 132, 2090–2098. [Google Scholar] [CrossRef]
  37. Iida-Klein, A.; Guo, J.; Takemura, M.; Drake, M.T.; Potts, J.T.; Abou-Samra, A.; Bringhurst, F.R.; Segre, G.V. Mutations in the Second Cytoplasmic Loop of the Rat Parathyroid Hormone (PTH)/PTH-Related Protein Receptor Result in Selective Loss of PTH-Stimulated Phospholipase C Activity. J. Biol. Chem. 1997, 272, 6882–6889. [Google Scholar] [CrossRef] [Green Version]
  38. Swarthout, J.T.; D’Alonzo, R.C.; Selvamurugan, N.; Partridge, N.C. Parathyroid Hormone-Dependent Signaling Pathways Regulating Genes in Bone Cells. Gene 2002, 282, 1–17. [Google Scholar] [CrossRef]
  39. Bastepe, M.; Weinstein, L.S.; Ogata, N.; Kawaguchi, H.; Jüppner, H.; Kronenberg, H.M.; Chung, U. Stimulatory G Protein Directly Regulates Hypertrophic Differentiation of Growth Plate Cartilage in Vivo. Proc. Natl. Acad. Sci. USA 2004, 101, 14794–14799. [Google Scholar] [CrossRef] [Green Version]
  40. Chung, U.I.; Lanske, B.; Lee, K.; Li, E.; Kronenberg, H. The Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor Coordinates Endochondral Bone Development by Directly Controlling Chondrocyte Differentiation. Proc. Natl. Acad. Sci. USA 1998, 95, 13030–13035. [Google Scholar] [CrossRef] [Green Version]
  41. Huang, W.; Chung, U.I.; Kronenberg, H.M.; de Crombrugghe, B. The Chondrogenic Transcription Factor Sox9 Is a Target of Signaling by the Parathyroid Hormone-Related Peptide in the Growth Plate of Endochondral Bones. Proc. Natl. Acad. Sci. USA 2001, 98, 160–165. [Google Scholar] [CrossRef]
  42. Correa, D.; Hesse, E.; Seriwatanachai, D.; Kiviranta, R.; Saito, H.; Yamana, K.; Neff, L.; Atfi, A.; Coillard, L.; Sitara, D.; et al. Zfp521 Is a Target Gene and Key Effector of Parathyroid Hormone-Related Peptide Signaling in Growth Plate Chondrocytes. Dev. Cell. 2010, 19, 533–546. [Google Scholar] [CrossRef] [Green Version]
  43. Guo, J.; Chung, U.-I.; Kondo, H.; Bringhurst, F.R.; Kronenberg, H.M. The PTH/PTHrP Receptor Can Delay Chondrocyte Hypertrophy in Vivo without Activating Phospholipase C. Dev. Cell. 2002, 3, 183–194. [Google Scholar] [CrossRef] [Green Version]
  44. Lee, K.; Deeds, J.D.; Segre, G.V. Expression of Parathyroid Hormone-Related Peptide and Its Receptor Messenger Ribonucleic Acids during Fetal Development of Rats. Endocrinology 1995, 136, 453–463. [Google Scholar] [CrossRef]
  45. Suda, N.; Gillespie, M.T.; Traianedes, K.; Zhou, H.; Ho, P.W.; Hards, D.K.; Allan, E.H.; Martin, T.J.; Moseley, J.M. Expression of Parathyroid Hormone-Related Protein in Cells of Osteoblast Lineage. J. Cell. Physiol. 1996, 166, 94–104. [Google Scholar] [CrossRef]
  46. Wang, M.; Nasiri, A.R.; Broadus, A.E.; Tommasini, S.M. Periosteal PTHrP Regulates Cortical Bone Remodeling During Fracture Healing. Bone 2015, 81, 104–111. [Google Scholar] [CrossRef] [Green Version]
  47. Blomstrand, S.; Claësson, I.; Säve-Söderbergh, J. A Case of Lethal Congenital Dwarfism with Accelerated Skeletal Maturation. Pediatr. Radiol. 1985, 15, 141–143. [Google Scholar] [CrossRef] [PubMed]
  48. Oostra, R.J.; van der Harten, J.J.; Rijnders, W.P.; Scott, R.J.; Young, M.P.; Trump, D. Blomstrand Osteochondrodysplasia: Three Novel Cases and Histological Evidence for Heterogeneity. Virchows Arch. 2000, 436, 28–35. [Google Scholar] [CrossRef]
  49. Jüppner, H.; Schipani, E. Receptors for Parathyroid Hormone and Parathyroid Hormone-Related Peptide: From Molecular Cloning to Definition of Diseases. Curr. Opin. Nephrol. Hypertens. 1996, 5, 300–306. [Google Scholar] [CrossRef]
  50. Duchatelet, S.; Ostergaard, E.; Cortes, D.; Lemainque, A.; Julier, C. Recessive Mutations in PTHR1 Cause Contrasting Skeletal Dysplasias in Eiken and Blomstrand Syndromes. Hum. Mol. Genet. 2005, 14, 1–5. [Google Scholar] [CrossRef] [PubMed]
  51. Klopocki, E.; Hennig, B.P.; Dathe, K.; Koll, R.; de Ravel, T.; Baten, E.; Blom, E.; Gillerot, Y.; Weigel, J.F.W.; Krüger, G.; et al. Deletion and Point Mutations of PTHLH Cause Brachydactyly Type E. Am. J. Hum. Genet. 2010, 86, 434–439. [Google Scholar] [CrossRef] [Green Version]
  52. Silve, C.; Le-Stunff, C.; Motte, E.; Gunes, Y.; Linglart, A.; Clauser, E. Acrodysostosis Syndromes. Bonekey Rep. 2012, 1, 225. [Google Scholar] [CrossRef] [Green Version]
  53. Linglart, A.; Fryssira, H.; Hiort, O.; Holterhus, P.-M.; Perez de Nanclares, G.; Argente, J.; Heinrichs, C.; Kuechler, A.; Mantovani, G.; Leheup, B.; et al. PRKAR1A and PDE4D Mutations Cause Acrodysostosis but Two Distinct Syndromes with or without GPCR-Signaling Hormone Resistance. J. Clin. Endocrinol. Metab. 2012, 97, E2328–E2338. [Google Scholar] [CrossRef] [Green Version]
  54. Patten, J.L.; Johns, D.R.; Valle, D.; Eil, C.; Gruppuso, P.A.; Steele, G.; Smallwood, P.M.; Levine, M.A. Mutation in the Gene Encoding the Stimulatory G Protein of Adenylate Cyclase in Albright’s Hereditary Osteodystrophy. N. Engl. J. Med. 1990, 322, 1412–1419. [Google Scholar] [CrossRef]
  55. Weinstein, L.S.; Gejman, P.V.; Friedman, E.; Kadowaki, T.; Collins, R.M.; Gershon, E.S.; Spiegel, A.M. Mutations of the Gs Alpha-Subunit Gene in Albright Hereditary Osteodystrophy Detected by Denaturing Gradient Gel Electrophoresis. Proc. Natl. Acad. Sci. USA 1990, 87, 8287–8290. [Google Scholar] [CrossRef] [Green Version]
  56. Mantovani, G.; de Sanctis, L.; Barbieri, A.M.; Elli, F.M.; Bollati, V.; Vaira, V.; Labarile, P.; Bondioni, S.; Peverelli, E.; Lania, A.G.; et al. Pseudohypoparathyroidism and GNAS Epigenetic Defects: Clinical Evaluation of Albright Hereditary Osteodystrophy and Molecular Analysis in 40 Patients. J. Clin. Endocrinol. Metab. 2010, 95, 651–658. [Google Scholar] [CrossRef] [Green Version]
  57. Alman, B.A.; Greel, D.A.; Wolfe, H.J. Activating Mutations of Gs Protein in Monostotic Fibrous Lesions of Bone. J. Orthop. Res. 1996, 14, 311–315. [Google Scholar] [CrossRef]
  58. Weinstein, L.S.; Shenker, A.; Gejman, P.V.; Merino, M.J.; Friedman, E.; Spiegel, A.M. Activating Mutations of the Stimulatory G Protein in the McCune-Albright Syndrome. N. Engl. J. Med. 1991, 325, 1688–1695. [Google Scholar] [CrossRef]
  59. Landis, C.A.; Masters, S.B.; Spada, A.; Pace, A.M.; Bourne, H.R.; Vallar, L. GTPase Inhibiting Mutations Activate the Alpha Chain of Gs and Stimulate Adenylyl Cyclase in Human Pituitary Tumours. Nature 1989, 340, 692–696. [Google Scholar] [CrossRef]
  60. Williams, S.R.; Aldred, M.A.; Der Kaloustian, V.M.; Halal, F.; Gowans, G.; McLeod, D.R.; Zondag, S.; Toriello, H.V.; Magenis, R.E.; Elsea, S.H. Haploinsufficiency of HDAC4 Causes Brachydactyly Mental Retardation Syndrome, with Brachydactyly Type E, Developmental Delays, and Behavioral Problems. Am. J. Hum. Genet. 2010, 87, 219–228. [Google Scholar] [CrossRef] [Green Version]
  61. Katoh, M. WNT and FGF Gene Clusters (Review). Int. J. Oncol. 2002, 21, 1269–1273. [Google Scholar] [CrossRef]
  62. Van Amerongen, R.; Nusse, R. Towards an Integrated View of Wnt Signaling in Development. Development 2009, 136, 3205–3214. [Google Scholar] [CrossRef] [Green Version]
  63. Kumar, D.; Lassar, A.B. The Transcriptional Activity of Sox9 in Chondrocytes Is Regulated by RhoA Signaling and Actin Polymerization. Mol. Cell. Biol. 2009, 29, 4262–4273. [Google Scholar] [CrossRef] [Green Version]
  64. Maupin, K.A.; Droscha, C.J.; Williams, B.O. A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-Catenin Signaling in Humans and Mice. Bone Res. 2013, 1, 27–71. [Google Scholar] [CrossRef] [Green Version]
  65. Li, Y.; Dudley, A.T. Noncanonical Frizzled Signaling Regulates Cell Polarity of Growth Plate Chondrocytes. Development 2009, 136, 1083–1092. [Google Scholar] [CrossRef] [Green Version]
  66. Yang, Y.; Topol, L.; Lee, H.; Wu, J. Wnt5a and Wnt5b Exhibit Distinct Activities in Coordinating Chondrocyte Proliferation and Differentiation. Development 2003, 130, 1003–1015. [Google Scholar] [CrossRef] [Green Version]
  67. Hartmann, C.; Tabin, C.J. Dual Roles of Wnt Signaling during Chondrogenesis in the Chicken Limb. Development 2000, 127, 3141–3159. [Google Scholar] [PubMed]
  68. Day, T.F.; Guo, X.; Garrett-Beal, L.; Yang, Y. Wnt/Beta-Catenin Signaling in Mesenchymal Progenitors Controls Osteoblast and Chondrocyte Differentiation during Vertebrate Skeletogenesis. Dev. Cell. 2005, 8, 739–750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Hill, T.P.; Später, D.; Taketo, M.M.; Birchmeier, W.; Hartmann, C. Canonical Wnt/Beta-Catenin Signaling Prevents Osteoblasts from Differentiating into Chondrocytes. Dev. Cell. 2005, 8, 727–738. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Hu, H.; Hilton, M.J.; Tu, X.; Yu, K.; Ornitz, D.M.; Long, F. Sequential Roles of Hedgehog and Wnt Signaling in Osteoblast Development. Development 2005, 132, 49–60. [Google Scholar] [CrossRef] [Green Version]
  71. Bennett, C.N.; Ouyang, H.; Ma, Y.L.; Zeng, Q.; Gerin, I.; Sousa, K.M.; Lane, T.F.; Krishnan, V.; Hankenson, K.D.; MacDougald, O.A. Wnt10b Increases Postnatal Bone Formation by Enhancing Osteoblast Differentiation. J. Bone Miner. Res. 2007, 22, 1924–1932. [Google Scholar] [CrossRef] [PubMed]
  72. Lu, Y.; Ren, X.; Wang, Y.; Bardai, G.; Sturm, M.; Dai, Y.; Riess, O.; Zhang, Y.; Li, H.; Li, T.; et al. Novel WNT1 Mutations in Children with Osteogenesis Imperfecta: Clinical and Functional Characterization. Bone 2018, 114, 144–149. [Google Scholar] [CrossRef] [PubMed]
  73. Niemann, S.; Zhao, C.; Pascu, F.; Stahl, U.; Aulepp, U.; Niswander, L.; Weber, J.L.; Müller, U. Homozygous WNT3 Mutation Causes Tetra-Amelia in a Large Consanguineous Family. Am. J. Hum. Genet. 2004, 74, 558–563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Person, A.D.; Beiraghi, S.; Sieben, C.M.; Hermanson, S.; Neumann, A.N.; Robu, M.E.; Schleiffarth, J.R.; Billington, C.J.; van Bokhoven, H.; Hoogeboom, J.M.; et al. WNT5A Mutations in Patients with Autosomal Dominant Robinow Syndrome. Dev. Dyn. 2010, 239, 327–337. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Thiele, H.; McCann, C.; van’t Padje, S.; Schwabe, G.C.; Hennies, H.C.; Camera, G.; Opitz, J.; Laxova, R.; Mundlos, S.; Nürnberg, P. Acropectorovertebral Dysgenesis (F Syndrome) Maps to Chromosome 2q36. J. Med. Genet. 2004, 41, 213–218. [Google Scholar] [CrossRef] [PubMed]
  76. Woods, C.G.; Stricker, S.; Seemann, P.; Stern, R.; Cox, J.; Sherridan, E.; Roberts, E.; Springell, K.; Scott, S.; Karbani, G.; et al. Mutations in WNT7A Cause a Range of Limb Malformations, Including Fuhrmann Syndrome and Al-Awadi/Raas-Rothschild/Schinzel Phocomelia Syndrome. Am. J. Hum. Genet. 2006, 79, 402–408. [Google Scholar] [CrossRef] [Green Version]
  77. Kantaputra, P.N.; Kapoor, S.; Verma, P.; Intachai, W.; Ketudat Cairns, J.R. Split Hand-Foot Malformation and a Novel WNT10B Mutation. Eur. J. Med. Genet. 2018, 61, 372–375. [Google Scholar] [CrossRef]
  78. Huybrechts, Y.; Mortier, G.; Boudin, E.; Van Hul, W. WNT Signaling and Bone: Lessons from Skeletal Dysplasias and Disorders. Front. Endocrinol. 2020, 11, 165. [Google Scholar] [CrossRef] [Green Version]
  79. Saal, H.M.; Prows, C.A.; Guerreiro, I.; Donlin, M.; Knudson, L.; Sund, K.L.; Chang, C.-F.; Brugmann, S.A.; Stottmann, R.W. A Mutation in FRIZZLED2 Impairs Wnt Signaling and Causes Autosomal Dominant Omodysplasia. Hum. Mol. Genet. 2015, 24, 3399–3409. [Google Scholar] [CrossRef] [Green Version]
  80. Schwabe, G.C.; Tinschert, S.; Buschow, C.; Meinecke, P.; Wolff, G.; Gillessen-Kaesbach, G.; Oldridge, M.; Wilkie, A.O.; Kömec, R.; Mundlos, S. Distinct Mutations in the Receptor Tyrosine Kinase Gene ROR2 Cause Brachydactyly Type B. Am. J. Hum. Genet. 2000, 67, 822–831. [Google Scholar] [CrossRef] [Green Version]
  81. Afzal, A.R.; Jeffery, S. One Gene, Two Phenotypes: ROR2 Mutations in Autosomal Recessive Robinow Syndrome and Autosomal Dominant Brachydactyly Type B. Hum. Mutat. 2003, 22, 1–11. [Google Scholar] [CrossRef]
  82. Levasseur, R.; Lacombe, D.; de Vernejoul, M.C. LRP5 Mutations in Osteoporosis-Pseudoglioma Syndrome and High-Bone-Mass Disorders. Jt. Bone Spine 2005, 72, 207–214. [Google Scholar] [CrossRef] [PubMed]
  83. Kwee, M.L.; Balemans, W.; Cleiren, E.; Gille, J.J.P.; Van Der Blij, F.; Sepers, J.M.; Van Hul, W. An Autosomal Dominant High Bone Mass Phenotype in Association with Craniosynostosis in an Extended Family Is Caused by an LRP5 Missense Mutation. J. Bone Miner. Res. 2005, 20, 1254–1260. [Google Scholar] [CrossRef]
  84. Korvala, J.; Jüppner, H.; Mäkitie, O.; Sochett, E.; Schnabel, D.; Mora, S.; Bartels, C.F.; Warman, M.L.; Deraska, D.; Cole, W.G.; et al. Mutations in LRP5 Cause Primary Osteoporosis without Features of OI by Reducing Wnt Signaling Activity. BMC Med. Genet. 2012, 13, 26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Fijalkowski, I.; Geets, E.; Steenackers, E.; Van Hoof, V.; Ramos, F.J.; Mortier, G.; Fortuna, A.M.; Van Hul, W.; Boudin, E. A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone. J. Bone Miner. Res. 2016, 31, 874–881. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Khan, T.N.; Klar, J.; Ali, Z.; Khan, F.; Baig, S.M.; Dahl, N. Cenani-Lenz Syndrome Restricted to Limb and Kidney Anomalies Associated with a Novel LRP4 Missense Mutation. Eur. J. Med. Genet. 2013, 56, 371–374. [Google Scholar] [CrossRef] [PubMed]
  87. Kariminejad, A.; Stollfuß, B.; Li, Y.; Bögershausen, N.; Boss, K.; Hennekam, R.C.M.; Wollnik, B. Severe Cenani-Lenz Syndrome Caused by Loss of LRP4 Function. Am. J. Med. Genet. Part A 2013, 161A, 1475–1479. [Google Scholar] [CrossRef]
  88. Little, R.D.; Recker, R.R.; Johnson, M.L. High Bone Density Due to a Mutation in LDL-Receptor-Related Protein 5. N. Engl. J. Med. 2002, 347, 943–944. [Google Scholar] [CrossRef]
  89. Perdu, B.; de Freitas, F.; Frints, S.G.M.; Schouten, M.; Schrander-Stumpel, C.; Barbosa, M.; Pinto-Basto, J.; Reis-Lima, M.; de Vernejoul, M.-C.; Becker, K.; et al. Osteopathia Striata with Cranial Sclerosis Owing to WTX Gene Defect. J. Bone Miner. Res. 2010, 25, 82–90. [Google Scholar] [CrossRef]
  90. Andersson, E.R.; Sandberg, R.; Lendahl, U. Notch Signaling: Simplicity in Design, Versatility in Function. Development 2011, 138, 3593–3612. [Google Scholar] [CrossRef] [Green Version]
  91. Kopan, R.; Goate, A. A Common Enzyme Connects Notch Signaling and Alzheimer’s Disease. Genes Dev. 2000, 14, 2799–2806. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Kopan, R.; Ilagan, M.X.G. The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism. Cell 2009, 137, 216–233. [Google Scholar] [CrossRef] [Green Version]
  93. Engin, F.; Lee, B. NOTCHing the Bone: Insights into Multi-Functionality. Bone 2010, 46, 274–280. [Google Scholar] [CrossRef] [Green Version]
  94. Dong, Y.; Jesse, A.M.; Kohn, A.; Gunnell, L.M.; Honjo, T.; Zuscik, M.J.; O’Keefe, R.J.; Hilton, M.J. RBPjkappa-Dependent Notch Signaling Regulates Mesenchymal Progenitor Cell Proliferation and Differentiation during Skeletal Development. Development 2010, 137, 1461–1471. [Google Scholar] [CrossRef] [Green Version]
  95. Mead, T.J.; Yutzey, K.E. Notch Pathway Regulation of Chondrocyte Differentiation and Proliferation during Appendicular and Axial Skeleton Development. Proc. Natl. Acad. Sci. USA 2009, 106, 14420–14425. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Hosaka, Y.; Saito, T.; Sugita, S.; Hikata, T.; Kobayashi, H.; Fukai, A.; Taniguchi, Y.; Hirata, M.; Akiyama, H.; Chung, U.; et al. Notch Signaling in Chondrocytes Modulates Endochondral Ossification and Osteoarthritis Development. Proc. Natl. Acad. Sci. USA 2013, 110, 1875–1880. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Chen, S.; Tao, J.; Bae, Y.; Jiang, M.-M.; Bertin, T.; Chen, Y.; Yang, T.; Lee, B. Notch Gain of Function Inhibits Chondrocyte Differentiation via Rbpj-Dependent Suppression of Sox9. J. Bone Miner. Res. 2013, 28, 649–659. [Google Scholar] [CrossRef] [PubMed]
  98. Feller, J.; Schneider, A.; Schuster-Gossler, K.; Gossler, A. Noncyclic Notch Activity in the Presomitic Mesoderm Demonstrates Uncoupling of Somite Compartmentalization and Boundary Formation. Genes Dev. 2008, 22, 2166–2171. [Google Scholar] [CrossRef] [Green Version]
  99. Ferjentsik, Z.; Hayashi, S.; Dale, J.K.; Bessho, Y.; Herreman, A.; De Strooper, B.; del Monte, G.; de la Pompa, J.L.; Maroto, M. Notch Is a Critical Component of the Mouse Somitogenesis Oscillator and Is Essential for the Formation of the Somites. PLoS Genet. 2009, 5, e1000662. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  100. Bulman, M.P.; Kusumi, K.; Frayling, T.M.; McKeown, C.; Garrett, C.; Lander, E.S.; Krumlauf, R.; Hattersley, A.T.; Ellard, S.; Turnpenny, P.D. Mutations in the Human Delta Homologue, DLL3, Cause Axial Skeletal Defects in Spondylocostal Dysostosis. Nat. Genet. 2000, 24, 438–441. [Google Scholar] [CrossRef]
  101. Kusumi, K.; Sun, E.S.; Kerrebrock, A.W.; Bronson, R.T.; Chi, D.C.; Bulotsky, M.S.; Spencer, J.B.; Birren, B.W.; Frankel, W.N.; Lander, E.S. The Mouse Pudgy Mutation Disrupts Delta Homologue Dll3 and Initiation of Early Somite Boundaries. Nat. Genet. 1998, 19, 274–278. [Google Scholar] [CrossRef]
  102. Bessho, Y.; Sakata, R.; Komatsu, S.; Shiota, K.; Yamada, S.; Kageyama, R. Dynamic Expression and Essential Functions of Hes7 in Somite Segmentation. Genes Dev. 2001, 15, 2642–2647. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Sparrow, D.B.; Chapman, G.; Wouters, M.A.; Whittock, N.V.; Ellard, S.; Fatkin, D.; Turnpenny, P.D.; Kusumi, K.; Sillence, D.; Dunwoodie, S.L. Mutation of the LUNATIC FRINGE Gene in Humans Causes Spondylocostal Dysostosis with a Severe Vertebral Phenotype. Am. J. Hum. Genet. 2006, 78, 28–37. [Google Scholar] [CrossRef] [Green Version]
  104. Sparrow, D.B.; Guillén-Navarro, E.; Fatkin, D.; Dunwoodie, S.L. Mutation of Hairy-and-Enhancer-of-Split-7 in Humans Causes Spondylocostal Dysostosis. Hum. Mol. Genet. 2008, 17, 3761–3766. [Google Scholar] [CrossRef] [Green Version]
  105. Sparrow, D.B.; Sillence, D.; Wouters, M.A.; Turnpenny, P.D.; Dunwoodie, S.L. Two Novel Missense Mutations in HAIRY-AND-ENHANCER-OF-SPLIT-7 in a Family with Spondylocostal Dysostosis. Eur. J. Hum. Genet. 2010, 18, 674–679. [Google Scholar] [CrossRef] [Green Version]
  106. Pakvasa, M.; Haravu, P.; Boachie-Mensah, M.; Jones, A.; Coalson, E.; Liao, J.; Zeng, Z.; Wu, D.; Qin, K.; Wu, X.; et al. Notch Signaling: Its Essential Roles in Bone and Craniofacial Development. Genes Dis. 2020, S2352304220300581. [Google Scholar] [CrossRef] [PubMed]
  107. Regan, J.; Long, F. Notch Signaling and Bone Remodeling. Curr. Osteoporos. Rep. 2013, 11, 126–129. [Google Scholar] [CrossRef] [Green Version]
  108. Tu, X.; Chen, J.; Lim, J.; Karner, C.M.; Lee, S.-Y.; Heisig, J.; Wiese, C.; Surendran, K.; Kopan, R.; Gessler, M.; et al. Physiological Notch Signaling Maintains Bone Homeostasis via RBPjk and Hey Upstream of NFATc1. PLoS Genet. 2012, 8, e1002577. [Google Scholar] [CrossRef] [Green Version]
  109. Hilton, M.J.; Tu, X.; Wu, X.; Bai, S.; Zhao, H.; Kobayashi, T.; Kronenberg, H.M.; Teitelbaum, S.L.; Ross, F.P.; Kopan, R.; et al. Notch Signaling Maintains Bone Marrow Mesenchymal Progenitors by Suppressing Osteoblast Differentiation. Nat. Med. 2008, 14, 306–314. [Google Scholar] [CrossRef] [Green Version]
  110. Engin, F.; Yao, Z.; Yang, T.; Zhou, G.; Bertin, T.; Jiang, M.M.; Chen, Y.; Wang, L.; Zheng, H.; Sutton, R.E.; et al. Dimorphic Effects of Notch Signaling in Bone Homeostasis. Nat. Med. 2008, 14, 299–305. [Google Scholar] [CrossRef] [PubMed]
  111. Isidor, B.; Lindenbaum, P.; Pichon, O.; Bézieau, S.; Dina, C.; Jacquemont, S.; Martin-Coignard, D.; Thauvin-Robinet, C.; Le Merrer, M.; Mandel, J.-L.; et al. Truncating Mutations in the Last Exon of NOTCH2 Cause a Rare Skeletal Disorder with Osteoporosis. Nat. Genet. 2011, 43, 306–308. [Google Scholar] [CrossRef]
  112. Canalis, E.; Zanotti, S. Hajdu-Cheney Syndrome, a Disease Associated with NOTCH2 Mutations. Curr. Osteoporos. Rep. 2016, 14, 126–131. [Google Scholar] [CrossRef] [Green Version]
  113. Hassed, S.; Li, S.; Mulvihill, J.; Aston, C.; Palmer, S. Adams-Oliver Syndrome Review of the Literature: Refining the Diagnostic Phenotype. Am. J. Med. Genet. Part A 2017, 173, 790–800. [Google Scholar] [CrossRef]
  114. Dudoignon, B.; Huber, C.; Michot, C.; Di Rocco, F.; Girard, M.; Lyonnet, S.; Rio, M.; Rabia, S.H.; Daire, V.C.; Baujat, G. Expanding the Phenotype in Adams-Oliver Syndrome Correlating with the Genotype. Am. J. Med. Genet. Part A 2020, 182, 29–37. [Google Scholar] [CrossRef]
  115. Feng, X.-H.; Derynck, R. Specificity and Versatility in Tgf-Beta Signaling through Smads. Annu. Rev. Cell. Dev. Biol. 2005, 21, 659–693. [Google Scholar] [CrossRef] [Green Version]
  116. Wagner, D.O.; Sieber, C.; Bhushan, R.; Börgermann, J.H.; Graf, D.; Knaus, P. BMPs: From Bone to Body Morphogenetic Proteins. Sci. Signal. 2010, 3, mr1. [Google Scholar] [CrossRef]
  117. Yi, J.J.; Barnes, A.P.; Hand, R.; Polleux, F.; Ehlers, M.D. TGF-Beta Signaling Specifies Axons during Brain Development. Cell 2010, 142, 144–157. [Google Scholar] [CrossRef] [Green Version]
  118. Wu, M.; Chen, G.; Li, Y.-P. TGF-β and BMP Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease. Bone Res. 2016, 4, 16009. [Google Scholar] [CrossRef]
  119. Furumatsu, T.; Ozaki, T.; Asahara, H. Smad3 Activates the Sox9-Dependent Transcription on Chromatin. Int. J. Biochem. Cell. Biol. 2009, 41, 1198–1204. [Google Scholar] [CrossRef] [Green Version]
  120. Mueller, M.B.; Tuan, R.S. Functional Characterization of Hypertrophy in Chondrogenesis of Human Mesenchymal Stem Cells. Arthritis Rheum. 2008, 58, 1377–1388. [Google Scholar] [CrossRef] [Green Version]
  121. Li, X.; Ionescu, A.M.; Schwarz, E.M.; Zhang, X.; Drissi, H.; Puzas, J.E.; Rosier, R.N.; Zuscik, M.J.; O’Keefe, R.J. Smad6 Is Induced by BMP-2 and Modulates Chondrocyte Differentiation. J. Orthop. Res. 2003, 21, 908–913. [Google Scholar] [CrossRef]
  122. Culbert, A.L.; Chakkalakal, S.A.; Theosmy, E.G.; Brennan, T.A.; Kaplan, F.S.; Shore, E.M. Alk2 Regulates Early Chondrogenic Fate in Fibrodysplasia Ossificans Progressiva Heterotopic Endochondral Ossification. Stem Cells 2014, 32, 1289–1300. [Google Scholar] [CrossRef] [Green Version]
  123. Derynck, R.; Akhurst, R.J. Differentiation Plasticity Regulated by TGF-Beta Family Proteins in Development and Disease. Nat. Cell Biol. 2007, 9, 1000–1004. [Google Scholar] [CrossRef] [PubMed]
  124. Loeys, B.L.; Chen, J.; Neptune, E.R.; Judge, D.P.; Podowski, M.; Holm, T.; Meyers, J.; Leitch, C.C.; Katsanis, N.; Sharifi, N.; et al. A Syndrome of Altered Cardiovascular, Craniofacial, Neurocognitive and Skeletal Development Caused by Mutations in TGFBR1 or TGFBR2. Nat. Genet. 2005, 37, 275–281. [Google Scholar] [CrossRef] [PubMed]
  125. Janssens, K.; Vanhoenacker, F.; Bonduelle, M.; Verbruggen, L.; Van Maldergem, L.; Ralston, S.; Guañabens, N.; Migone, N.; Wientroub, S.; Divizia, M.T.; et al. Camurati-Engelmann Disease: Review of the Clinical, Radiological, and Molecular Data of 24 Families and Implications for Diagnosis and Treatment. J. Med. Genet. 2006, 43, 1–11. [Google Scholar] [CrossRef] [PubMed]
  126. Saito, T.; Kinoshita, A.; Yoshiura, K.; Makita, Y.; Wakui, K.; Honke, K.; Niikawa, N.; Taniguchi, N. Domain-Specific Mutations of a Transforming Growth Factor (TGF)-Beta 1 Latency-Associated Peptide Cause Camurati-Engelmann Disease Because of the Formation of a Constitutively Active Form of TGF-Beta 1. J. Biol. Chem. 2001, 276, 11469–11472. [Google Scholar] [CrossRef] [Green Version]
  127. Luu, H.H.; Song, W.-X.; Luo, X.; Manning, D.; Luo, J.; Deng, Z.-L.; Sharff, K.A.; Montag, A.G.; Haydon, R.C.; He, T.-C. Distinct Roles of Bone Morphogenetic Proteins in Osteogenic Differentiation of Mesenchymal Stem Cells. J. Orthop. Res. 2007, 25, 665–677. [Google Scholar] [CrossRef]
  128. Lin, S.; Svoboda, K.K.H.; Feng, J.Q.; Jiang, X. The Biological Function of Type I Receptors of Bone Morphogenetic Protein in Bone. Bone Res. 2016, 4, 16005. [Google Scholar] [CrossRef] [Green Version]
  129. Stange, K.; Désir, J.; Kakar, N.; Mueller, T.D.; Budde, B.S.; Gordon, C.T.; Horn, D.; Seemann, P.; Borck, G. A Hypomorphic BMPR1B Mutation Causes Du Pan Acromesomelic Dysplasia. Orphanet. J. Rare. Dis. 2015, 10, 84. [Google Scholar] [CrossRef] [Green Version]
  130. Tassabehji, M.; Fang, Z.M.; Hilton, E.N.; McGaughran, J.; Zhao, Z.; de Bock, C.E.; Howard, E.; Malass, M.; Donnai, D.; Diwan, A.; et al. Mutations in GDF6 Are Associated with Vertebral Segmentation Defects in Klippel-Feil Syndrome. Hum. Mutat. 2008, 29, 1017–1027. [Google Scholar] [CrossRef]
  131. Le Goff, C.; Michot, C.; Cormier-Daire, V. Myhre Syndrome. Clin. Genet. 2014, 85, 503–513. [Google Scholar] [CrossRef] [PubMed]
  132. Gong, Y.; Krakow, D.; Marcelino, J.; Wilkin, D.; Chitayat, D.; Babul-Hirji, R.; Hudgins, L.; Cremers, C.W.; Cremers, F.P.; Brunner, H.G.; et al. Heterozygous Mutations in the Gene Encoding Noggin Affect Human Joint Morphogenesis. Nat. Genet. 1999, 21, 302–304. [Google Scholar] [CrossRef] [PubMed]
  133. Lehmann, K.; Seemann, P.; Silan, F.; Goecke, T.O.; Irgang, S.; Kjaer, K.W.; Kjaergaard, S.; Mahoney, M.J.; Morlot, S.; Reissner, C.; et al. A New Subtype of Brachydactyly Type B Caused by Point Mutations in the Bone Morphogenetic Protein Antagonist NOGGIN. Am. J. Hum. Genet. 2007, 81, 388–396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  134. Zong, Z.; Tees, S.; Miyanji, F.; Fauth, C.; Reilly, C.; Lopez, E.; Tredwell, S.; Paul Goldberg, Y.; Delaney, A.; Eydoux, P.; et al. BMPER Variants Associated with a Novel, Attenuated Subtype of Diaphanospondylodysostosis. J. Hum. Genet. 2015, 60, 743–747. [Google Scholar] [CrossRef]
  135. Hellemans, J.; Preobrazhenska, O.; Willaert, A.; Debeer, P.; Verdonk, P.C.M.; Costa, T.; Janssens, K.; Menten, B.; Van Roy, N.; Vermeulen, S.J.T.; et al. Loss-of-Function Mutations in LEMD3 Result in Osteopoikilosis, Buschke-Ollendorff Syndrome and Melorheostosis. Nat. Genet. 2004, 36, 1213–1218. [Google Scholar] [CrossRef] [PubMed]
  136. Doyle, A.J.; Doyle, J.J.; Bessling, S.L.; Maragh, S.; Lindsay, M.E.; Schepers, D.; Gillis, E.; Mortier, G.; Homfray, T.; Sauls, K.; et al. Mutations in the TGF-β Repressor SKI Cause Shprintzen-Goldberg Syndrome with Aortic Aneurysm. Nat. Genet. 2012, 44, 1249–1254. [Google Scholar] [CrossRef] [Green Version]
  137. Goetz, R.; Mohammadi, M. Exploring Mechanisms of FGF Signalling through the Lens of Structural Biology. Nat. Rev. Mol. Cell. Biol. 2013, 14, 166–180. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  138. Ornitz, D.M.; Itoh, N. The Fibroblast Growth Factor Signaling Pathway. Wiley Interdiscip. Rev. Dev. Biol. 2015, 4, 215–266. [Google Scholar] [CrossRef] [Green Version]
  139. Jacob, A.L.; Smith, C.; Partanen, J.; Ornitz, D.M. Fibroblast Growth Factor Receptor 1 Signaling in the Osteo-Chondrogenic Cell Lineage Regulates Sequential Steps of Osteoblast Maturation. Dev. Biol. 2006, 296, 315–328. [Google Scholar] [CrossRef] [Green Version]
  140. Ornitz, D.M.; Marie, P.J. FGF Signaling Pathways in Endochondral and Intramembranous Bone Development and Human Genetic Disease. Genes Dev. 2002, 16, 1446–1465. [Google Scholar] [CrossRef] [Green Version]
  141. Iwata, T.; Chen, L.; Li, C.; Ovchinnikov, D.A.; Behringer, R.R.; Francomano, C.A.; Deng, C.X. A Neonatal Lethal Mutation in FGFR3 Uncouples Proliferation and Differentiation of Growth Plate Chondrocytes in Embryos. Hum. Mol. Genet. 2000, 9, 1603–1613. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  142. Hung, I.H.; Yu, K.; Lavine, K.J.; Ornitz, D.M. FGF9 Regulates Early Hypertrophic Chondrocyte Differentiation and Skeletal Vascularization in the Developing Stylopod. Dev. Biol. 2007, 307, 300–313. [Google Scholar] [CrossRef] [Green Version]
  143. Colvin, J.S.; Bohne, B.A.; Harding, G.W.; McEwen, D.G.; Ornitz, D.M. Skeletal Overgrowth and Deafness in Mice Lacking Fibroblast Growth Factor Receptor 3. Nat. Genet. 1996, 12, 390–397. [Google Scholar] [CrossRef]
  144. Iwata, T.; Li, C.L.; Deng, C.X.; Francomano, C.A. Highly Activated Fgfr3 with the K644M Mutation Causes Prolonged Survival in Severe Dwarf Mice. Hum. Mol. Genet. 2001, 10, 1255–1264. [Google Scholar] [CrossRef] [Green Version]
  145. Liu, Z.; Lavine, K.J.; Hung, I.H.; Ornitz, D.M. FGF18 Is Required for Early Chondrocyte Proliferation, Hypertrophy and Vascular Invasion of the Growth Plate. Dev. Biol. 2007, 302, 80–91. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  146. Yu, K.; Xu, J.; Liu, Z.; Sosic, D.; Shao, J.; Olson, E.N.; Towler, D.A.; Ornitz, D.M. Conditional Inactivation of FGF Receptor 2 Reveals an Essential Role for FGF Signaling in the Regulation of Osteoblast Function and Bone Growth. Development 2003, 130, 3063–3074. [Google Scholar] [CrossRef] [Green Version]
  147. Eswarakumar, V.P.; Horowitz, M.C.; Locklin, R.; Morriss-Kay, G.M.; Lonai, P. A Gain-of-Function Mutation of Fgfr2c Demonstrates the Roles of This Receptor Variant in Osteogenesis. Proc. Natl. Acad. Sci. USA 2004, 101, 12555–12560. [Google Scholar] [CrossRef] [Green Version]
  148. Valverde-Franco, G.; Liu, H.; Davidson, D.; Chai, S.; Valderrama-Carvajal, H.; Goltzman, D.; Ornitz, D.M.; Henderson, J.E. Defective Bone Mineralization and Osteopenia in Young Adult FGFR3-/- Mice. Hum. Mol. Genet. 2004, 13, 271–284. [Google Scholar] [CrossRef] [Green Version]
  149. Rousseau, F.; Bonaventure, J.; Legeai-Mallet, L.; Pelet, A.; Rozet, J.M.; Maroteaux, P.; Le Merrer, M.; Munnich, A. Mutations in the Gene Encoding Fibroblast Growth Factor Receptor-3 in Achondroplasia. Nature 1994, 371, 252–254. [Google Scholar] [CrossRef]
  150. Shiang, R.; Thompson, L.M.; Zhu, Y.Z.; Church, D.M.; Fielder, T.J.; Bocian, M.; Winokur, S.T.; Wasmuth, J.J. Mutations in the Transmembrane Domain of FGFR3 Cause the Most Common Genetic Form of Dwarfism, Achondroplasia. Cell 1994, 78, 335–342. [Google Scholar] [CrossRef]
  151. Henderson, J.E.; Naski, M.C.; Aarts, M.M.; Wang, D.; Cheng, L.; Goltzman, D.; Ornitz, D.M. Expression of FGFR3 with the G380R Achondroplasia Mutation Inhibits Proliferation and Maturation of CFK2 Chondrocytic Cells. J. Bone Miner. Res. 2000, 15, 155–165. [Google Scholar] [CrossRef]
  152. Legeai-Mallet, L.; Benoist-Lasselin, C.; Delezoide, A.L.; Munnich, A.; Bonaventure, J. Fibroblast Growth Factor Receptor 3 Mutations Promote Apoptosis but Do Not Alter Chondrocyte Proliferation in Thanatophoric Dysplasia. J. Biol. Chem. 1998, 273, 13007–13014. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  153. Naski, M.C.; Wang, Q.; Xu, J.; Ornitz, D.M. Graded Activation of Fibroblast Growth Factor Receptor 3 by Mutations Causing Achondroplasia and Thanatophoric Dysplasia. Nat. Genet. 1996, 13, 233–237. [Google Scholar] [CrossRef] [PubMed]
  154. Pannier, S.; Couloigner, V.; Messaddeq, N.; Elmaleh-Bergès, M.; Munnich, A.; Romand, R.; Legeai-Mallet, L. Activating Fgfr3 Y367C Mutation Causes Hearing Loss and Inner Ear Defect in a Mouse Model of Chondrodysplasia. Biochim. Biophys. Acta 2009, 1792, 140–147. [Google Scholar] [CrossRef] [Green Version]
  155. Heuertz, S.; Le Merrer, M.; Zabel, B.; Wright, M.; Legeai-Mallet, L.; Cormier-Daire, V.; Gibbs, L.; Bonaventure, J. Novel FGFR3 Mutations Creating Cysteine Residues in the Extracellular Domain of the Receptor Cause Achondroplasia or Severe Forms of Hypochondroplasia. Eur. J. Hum. Genet. 2006, 14, 1240–1247. [Google Scholar] [CrossRef]
  156. Bonaventure, J.; Rousseau, F.; Legeai-Mallet, L.; Le Merrer, M.; Munnich, A.; Maroteaux, P. Common Mutations in the Fibroblast Growth Factor Receptor 3 (FGFR 3) Gene Account for Achondroplasia, Hypochondroplasia, and Thanatophoric Dwarfism. Am. J. Med. Genet. 1996, 63, 148–154. [Google Scholar] [CrossRef]
  157. Cohen, M.M. Achondroplasia, Hypochondroplasia and Thanatophoric Dysplasia: Clinically Related Skeletal Dysplasias That Are Also Related at the Molecular Level. Int. J. Oral. Maxillofac. Surg. 1998, 27, 451–455. [Google Scholar] [CrossRef]
  158. Tavormina, P.L.; Bellus, G.A.; Webster, M.K.; Bamshad, M.J.; Fraley, A.E.; McIntosh, I.; Szabo, J.; Jiang, W.; Jabs, E.W.; Wilcox, W.R.; et al. A Novel Skeletal Dysplasia with Developmental Delay and Acanthosis Nigricans Is Caused by a Lys650Met Mutation in the Fibroblast Growth Factor Receptor 3 Gene. Am. J. Hum. Genet. 1999, 64, 722–731. [Google Scholar] [CrossRef] [Green Version]
  159. Bellus, G.A.; Bamshad, M.J.; Przylepa, K.A.; Dorst, J.; Lee, R.R.; Hurko, O.; Jabs, E.W.; Curry, C.J.; Wilcox, W.R.; Lachman, R.S.; et al. Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans (SADDAN): Phenotypic Analysis of a New Skeletal Dysplasia Caused by a Lys650Met Mutation in Fibroblast Growth Factor Receptor 3. Am. J. Med. Genet. 1999, 85, 53–65. [Google Scholar] [CrossRef]
  160. Toydemir, R.M.; Brassington, A.E.; Bayrak-Toydemir, P.; Krakowiak, P.A.; Jorde, L.B.; Whitby, F.G.; Longo, N.; Viskochil, D.H.; Carey, J.C.; Bamshad, M.J. A Novel Mutation in FGFR3 Causes Camptodactyly, Tall Stature, and Hearing Loss (CATSHL) Syndrome. Am. J. Hum. Genet. 2006, 79, 935–941. [Google Scholar] [CrossRef] [Green Version]
  161. Makrythanasis, P.; Temtamy, S.; Aglan, M.S.; Otaify, G.A.; Hamamy, H.; Antonarakis, S.E. A Novel Homozygous Mutation in FGFR3 Causes Tall Stature, Severe Lateral Tibial Deviation, Scoliosis, Hearing Impairment, Camptodactyly, and Arachnodactyly. Hum. Mutat. 2014, 35, 959–963. [Google Scholar] [CrossRef] [PubMed]
  162. Rohmann, E.; Brunner, H.G.; Kayserili, H.; Uyguner, O.; Nürnberg, G.; Lew, E.D.; Dobbie, A.; Eswarakumar, V.P.; Uzumcu, A.; Ulubil-Emeroglu, M.; et al. Mutations in Different Components of FGF Signaling in LADD Syndrome. Nat. Genet. 2006, 38, 414–417. [Google Scholar] [CrossRef] [PubMed]
  163. Meyer, M.; Müller, A.-K.; Yang, J.; Moik, D.; Ponzio, G.; Ornitz, D.M.; Grose, R.; Werner, S. FGF Receptors 1 and 2 Are Key Regulators of Keratinocyte Migration in Vitro and in Wounded Skin. J. Cell. Sci. 2012, 125, 5690–5701. [Google Scholar] [CrossRef] [Green Version]
  164. Muenke, M.; Gripp, K.W.; McDonald-McGinn, D.M.; Gaudenz, K.; Whitaker, L.A.; Bartlett, S.P.; Markowitz, R.I.; Robin, N.H.; Nwokoro, N.; Mulvihill, J.J.; et al. A Unique Point Mutation in the Fibroblast Growth Factor Receptor 3 Gene (FGFR3) Defines a New Craniosynostosis Syndrome. Am. J. Hum. Genet. 1997, 60, 555–564. [Google Scholar] [PubMed]
  165. Chun, K.; Siegel-Bartelt, J.; Chitayat, D.; Phillips, J.; Ray, P.N. FGFR2 Mutation Associated with Clinical Manifestations Consistent with Antley-Bixler Syndrome. Am. J. Med. Genet. 1998, 77, 219–224. [Google Scholar] [CrossRef]
  166. Paznekas, W.A.; Cunningham, M.L.; Howard, T.D.; Korf, B.R.; Lipson, M.H.; Grix, A.W.; Feingold, M.; Goldberg, R.; Borochowitz, Z.; Aleck, K.; et al. Genetic Heterogeneity of Saethre-Chotzen Syndrome, Due to TWIST and FGFR Mutations. Am. J. Hum. Genet. 1998, 62, 1370–1380. [Google Scholar] [CrossRef] [Green Version]
  167. Przylepa, K.A.; Paznekas, W.; Zhang, M.; Golabi, M.; Bias, W.; Bamshad, M.J.; Carey, J.C.; Hall, B.D.; Stevenson, R.; Orlow, S.; et al. Fibroblast Growth Factor Receptor 2 Mutations in Beare-Stevenson Cutis Gyrata Syndrome. Nat. Genet. 1996, 13, 492–494. [Google Scholar] [CrossRef]
  168. Muenke, M.; Schell, U.; Hehr, A.; Robin, N.H.; Losken, H.W.; Schinzel, A.; Pulleyn, L.J.; Rutland, P.; Reardon, W.; Malcolm, S. A Common Mutation in the Fibroblast Growth Factor Receptor 1 Gene in Pfeiffer Syndrome. Nat. Genet. 1994, 8, 269–274. [Google Scholar] [CrossRef]
  169. Roscioli, T.; Flanagan, S.; Kumar, P.; Masel, J.; Gattas, M.; Hyland, V.J.; Glass, I.A. Clinical Findings in a Patient with FGFR1 P252R Mutation and Comparison with the Literature. Am. J. Med. Genet. 2000, 93, 22–28. [Google Scholar] [CrossRef]
  170. Simonis, N.; Migeotte, I.; Lambert, N.; Perazzolo, C.; de Silva, D.C.; Dimitrov, B.; Heinrichs, C.; Janssens, S.; Kerr, B.; Mortier, G.; et al. FGFR1 Mutations Cause Hartsfield Syndrome, the Unique Association of Holoprosencephaly and Ectrodactyly. J. Med. Genet. 2013, 50, 585–592. [Google Scholar] [CrossRef] [Green Version]
  171. White, K.E.; Cabral, J.M.; Davis, S.I.; Fishburn, T.; Evans, W.E.; Ichikawa, S.; Fields, J.; Yu, X.; Shaw, N.J.; McLellan, N.J.; et al. Mutations That Cause Osteoglophonic Dysplasia Define Novel Roles for FGFR1 in Bone Elongation. Am. J. Hum. Genet. 2005, 76, 361–367. [Google Scholar] [CrossRef] [Green Version]
  172. Wu, X.-L.; Gu, M.-M.; Huang, L.; Liu, X.-S.; Zhang, H.-X.; Ding, X.-Y.; Xu, J.-Q.; Cui, B.; Wang, L.; Lu, S.-Y.; et al. Multiple Synostoses Syndrome Is Due to a Missense Mutation in Exon 2 of FGF9 Gene. Am. J. Hum. Genet. 2009, 85, 53–63. [Google Scholar] [CrossRef] [Green Version]
  173. Milunsky, J.M.; Zhao, G.; Maher, T.A.; Colby, R.; Everman, D.B. LADD Syndrome Is Caused by FGF10 Mutations. Clin. Genet. 2006, 69, 349–354. [Google Scholar] [CrossRef]
  174. ADHR. Consortium Autosomal Dominant Hypophosphataemic Rickets Is Associated with Mutations in FGF23. Nat. Genet. 2000, 26, 345–348. [Google Scholar] [CrossRef]
  175. Liu, S.; Quarles, L.D. How Fibroblast Growth Factor 23 Works. J. Am. Soc. Nephrol. 2007, 18, 1637–1647. [Google Scholar] [CrossRef] [Green Version]
  176. Ozasa, A.; Komatsu, Y.; Yasoda, A.; Miura, M.; Sakuma, Y.; Nakatsuru, Y.; Arai, H.; Itoh, N.; Nakao, K. Complementary Antagonistic Actions between C-Type Natriuretic Peptide and the MAPK Pathway through FGFR-3 in ATDC5 Cells. Bone 2005, 36, 1056–1064. [Google Scholar] [CrossRef] [Green Version]
  177. Krejci, P. Interaction of Fibroblast Growth Factor and C-Natriuretic Peptide Signaling in Regulation of Chondrocyte Proliferation and Extracellular Matrix Homeostasis. J. Cell Sci. 2005, 118, 5089–5100. [Google Scholar] [CrossRef] [Green Version]
  178. Bartels, C.F.; Bükülmez, H.; Padayatti, P.; Rhee, D.K.; van Ravenswaaij-Arts, C.; Pauli, R.M.; Mundlos, S.; Chitayat, D.; Shih, L.-Y.; Al-Gazali, L.I.; et al. Mutations in the Transmembrane Natriuretic Peptide Receptor NPR-B Impair Skeletal Growth and Cause Acromesomelic Dysplasia, Type Maroteaux. Am. J. Hum. Genet. 2004, 75, 27–34. [Google Scholar] [CrossRef] [Green Version]
  179. Miura, K.; Namba, N.; Fujiwara, M.; Ohata, Y.; Ishida, H.; Kitaoka, T.; Kubota, T.; Hirai, H.; Higuchi, C.; Tsumaki, N.; et al. An Overgrowth Disorder Associated with Excessive Production of CGMP Due to a Gain-of-Function Mutation of the Natriuretic Peptide Receptor 2 Gene. PLoS ONE 2012, 7, e42180. [Google Scholar] [CrossRef] [Green Version]
  180. Barna, M.; Niswander, L. Visualization of Cartilage Formation: Insight into Cellular Properties of Skeletal Progenitors and Chondrodysplasia Syndromes. Dev. Cell. 2007, 12, 931–941. [Google Scholar] [CrossRef] [Green Version]
  181. Smits, P.; Li, P.; Mandel, J.; Zhang, Z.; Deng, J.M.; Behringer, R.R.; de Crombrugghe, B.; Lefebvre, V. The Transcription Factors L-Sox5 and Sox6 Are Essential for Cartilage Formation. Dev. Cell. 2001, 1, 277–290. [Google Scholar] [CrossRef] [Green Version]
  182. Dy, P.; Wang, W.; Bhattaram, P.; Wang, Q.; Wang, L.; Ballock, R.T.; Lefebvre, V. Sox9 Directs Hypertrophic Maturation and Blocks Osteoblast Differentiation of Growth Plate Chondrocytes. Dev. Cell. 2012, 22, 597–609. [Google Scholar] [CrossRef] [Green Version]
  183. Akiyama, H.; Lyons, J.P.; Mori-Akiyama, Y.; Yang, X.; Zhang, R.; Zhang, Z.; Deng, J.M.; Taketo, M.M.; Nakamura, T.; Behringer, R.R.; et al. Interactions between Sox9 and Beta-Catenin Control Chondrocyte Differentiation. Genes Dev. 2004, 18, 1072–1087. [Google Scholar] [CrossRef] [Green Version]
  184. Topol, L.; Chen, W.; Song, H.; Day, T.F.; Yang, Y. Sox9 Inhibits Wnt Signaling by Promoting Beta-Catenin Phosphorylation in the Nucleus. J. Biol. Chem. 2009, 284, 3323–3333. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  185. Zhou, G.; Zheng, Q.; Engin, F.; Munivez, E.; Chen, Y.; Sebald, E.; Krakow, D.; Lee, B. Dominance of SOX9 Function over RUNX2 during Skeletogenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 19004–19009. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  186. Hattori, T.; Müller, C.; Gebhard, S.; Bauer, E.; Pausch, F.; Schlund, B.; Bösl, M.R.; Hess, A.; Surmann-Schmitt, C.; von der Mark, H.; et al. SOX9 Is a Major Negative Regulator of Cartilage Vascularization, Bone Marrow Formation and Endochondral Ossification. Development 2010, 137, 901–911. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  187. Leung, V.Y.L.; Gao, B.; Leung, K.K.H.; Melhado, I.G.; Wynn, S.L.; Au, T.Y.K.; Dung, N.W.F.; Lau, J.Y.B.; Mak, A.C.Y.; Chan, D.; et al. SOX9 Governs Differentiation Stage-Specific Gene Expression in Growth Plate Chondrocytes via Direct Concomitant Transactivation and Repression. PLoS Genet. 2011, 7, e1002356. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  188. Foster, J.W.; Dominguez-Steglich, M.A.; Guioli, S.; Kwok, C.; Weller, P.A.; Stevanović, M.; Weissenbach, J.; Mansour, S.; Young, I.D.; Goodfellow, P.N. Campomelic Dysplasia and Autosomal Sex Reversal Caused by Mutations in an SRY-Related Gene. Nature 1994, 372, 525–530. [Google Scholar] [CrossRef] [PubMed]
  189. Wagner, T.; Wirth, J.; Meyer, J.; Zabel, B.; Held, M.; Zimmer, J.; Pasantes, J.; Bricarelli, F.D.; Keutel, J.; Hustert, E.; et al. Autosomal Sex Reversal and Campomelic Dysplasia Are Caused by Mutations in and around the SRY-Related Gene SOX9. Cell 1994, 79, 1111–1120. [Google Scholar] [CrossRef]
  190. Csukasi, F.; Duran, I.; Zhang, W.; Martin, J.H.; Barad, M.; Bamshad, M.; Weis, M.A.; Eyre, D.; Krakow, D.; Cohn, D.H. Dominant-Negative SOX9 Mutations in Campomelic Dysplasia. Hum. Mutat. 2019, 40, 2344–2352. [Google Scholar] [CrossRef]
  191. Komori, T. Signaling Networks in RUNX2-Dependent Bone Development. J. Cell. Biochem. 2011, 112, 750–755. [Google Scholar] [CrossRef]
  192. Akiyama, H.; Chaboissier, M.-C.; Martin, J.F.; Schedl, A.; de Crombrugghe, B. The Transcription Factor Sox9 Has Essential Roles in Successive Steps of the Chondrocyte Differentiation Pathway and Is Required for Expression of Sox5 and Sox6. Genes Dev. 2002, 16, 2813–2828. [Google Scholar] [CrossRef] [Green Version]
  193. Inada, M.; Yasui, T.; Nomura, S.; Miyake, S.; Deguchi, K.; Himeno, M.; Sato, M.; Yamagiwa, H.; Kimura, T.; Yasui, N.; et al. Maturational Disturbance of Chondrocytes in Cbfa1-Deficient Mice. Dev. Dyn. 1999, 214, 279–290. [Google Scholar] [CrossRef]
  194. Kim, I.S.; Otto, F.; Zabel, B.; Mundlos, S. Regulation of Chondrocyte Differentiation by Cbfa1. Mech. Dev. 1999, 80, 159–170. [Google Scholar] [CrossRef]
  195. Drissi, M.H.; Li, X.; Sheu, T.J.; Zuscik, M.J.; Schwarz, E.M.; Puzas, J.E.; Rosier, R.N.; O’Keefe, R.J. Runx2/Cbfa1 Stimulation by Retinoic Acid Is Potentiated by BMP2 Signaling through Interaction with Smad1 on the Collagen X Promoter in Chondrocytes. J. Cell Biochem. 2003, 90, 1287–1298. [Google Scholar] [CrossRef] [PubMed]
  196. Zheng, Q.; Zhou, G.; Morello, R.; Chen, Y.; Garcia-Rojas, X.; Lee, B. Type X Collagen Gene Regulation by Runx2 Contributes Directly to Its Hypertrophic Chondrocyte-Specific Expression in Vivo. J. Cell. Biol. 2003, 162, 833–842. [Google Scholar] [CrossRef] [PubMed]
  197. Selvamurugan, N.; Pulumati, M.R.; Tyson, D.R.; Partridge, N.C. Parathyroid Hormone Regulation of the Rat Collagenase-3 Promoter by Protein Kinase A-Dependent Transactivation of Core Binding Factor Alpha1. J. Biol. Chem. 2000, 275, 5037–5042. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  198. Javed, A.; Bae, J.-S.; Afzal, F.; Gutierrez, S.; Pratap, J.; Zaidi, S.K.; Lou, Y.; van Wijnen, A.J.; Stein, J.L.; Stein, G.S.; et al. Structural Coupling of Smad and Runx2 for Execution of the BMP2 Osteogenic Signal. J. Biol. Chem. 2008, 283, 8412–8422. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  199. Hinoi, E.; Bialek, P.; Chen, Y.-T.; Rached, M.-T.; Groner, Y.; Behringer, R.R.; Ornitz, D.M.; Karsenty, G. Runx2 Inhibits Chondrocyte Proliferation and Hypertrophy through Its Expression in the Perichondrium. Genes Dev. 2006, 20, 2937–2942. [Google Scholar] [CrossRef] [Green Version]
  200. Stricker, S.; Fundele, R.; Vortkamp, A.; Mundlos, S. Role of Runx Genes in Chondrocyte Differentiation. Dev. Biol. 2002, 245, 95–108. [Google Scholar] [CrossRef] [Green Version]
  201. Qin, X.; Jiang, Q.; Miyazaki, T.; Komori, T. Runx2 Regulates Cranial Suture Closure by Inducing Hedgehog, Fgf, Wnt and Pthlh Signaling Pathway Gene Expressions in Suture Mesenchymal Cells. Hum. Mol. Genet. 2019, 28, 896–911. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  202. Ducy, P.; Starbuck, M.; Priemel, M.; Shen, J.; Pinero, G.; Geoffroy, V.; Amling, M.; Karsenty, G. A Cbfa1-Dependent Genetic Pathway Controls Bone Formation beyond Embryonic Development. Genes Dev. 1999, 13, 1025–1036. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  203. Mundlos, S. Cleidocranial Dysplasia: Clinical and Molecular Genetics. J. Med. Genet. 1999, 36, 177–182. [Google Scholar]
  204. Guo, Y.-W.; Chiu, C.-Y.; Liu, C.-L.; Jap, T.-S.; Lin, L.-Y. Novel Mutation of RUNX2 Gene in a Patient with Cleidocranial Dysplasia. Int. J. Clin. Exp. Pathol. 2015, 8, 1057–1062. [Google Scholar]
  205. Moffatt, P.; Ben Amor, M.; Glorieux, F.H.; Roschger, P.; Klaushofer, K.; Schwartzentruber, J.A.; Paterson, A.D.; Hu, P.; Marshall, C.; FORGE Canada Consortium; et al. Metaphyseal Dysplasia with Maxillary Hypoplasia and Brachydactyly Is Caused by a Duplication in RUNX2. Am. J. Hum. Genet. 2013, 92, 252–258. [Google Scholar] [CrossRef] [Green Version]
  206. Al-Yassin, A.; Calder, A.D.; Harrison, M.; Lester, T.; Lord, H.; Oldridge, M.; Watkins, S.; Keen, R.; Wakeling, E.L. A Three-Generation Family with Metaphyseal Dysplasia, Maxillary Hypoplasia and Brachydactyly (MDMHB) Due to Intragenic RUNX2 Duplication. Eur. J. Hum. Genet. 2018, 26, 1288–1293. [Google Scholar] [CrossRef] [Green Version]
  207. Zou, L.; Zou, X.; Li, H.; Mygind, T.; Zeng, Y.; Lü, N.; Bünger, C. Molecular Mechanism of Osteochondroprogenitor Fate Determination during Bone Formation. Adv. Exp. Med. Biol. 2006, 585, 431–441. [Google Scholar] [CrossRef] [PubMed]
  208. Zhou, X.; Zhang, Z.; Feng, J.Q.; Dusevich, V.M.; Sinha, K.; Zhang, H.; Darnay, B.G.; de Crombrugghe, B. Multiple Functions of Osterix Are Required for Bone Growth and Homeostasis in Postnatal Mice. Proc. Natl. Acad. Sci. USA 2010, 107, 12919–12924. [Google Scholar] [CrossRef] [Green Version]
  209. Nakashima, K.; Zhou, X.; Kunkel, G.; Zhang, Z.; Deng, J.M.; Behringer, R.R.; de Crombrugghe, B. The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation. Cell 2002, 108, 17–29. [Google Scholar] [CrossRef] [Green Version]
  210. Nishimura, R.; Wakabayashi, M.; Hata, K.; Matsubara, T.; Honma, S.; Wakisaka, S.; Kiyonari, H.; Shioi, G.; Yamaguchi, A.; Tsumaki, N.; et al. Osterix Regulates Calcification and Degradation of Chondrogenic Matrices through Matrix Metalloproteinase 13 (MMP13) Expression in Association with Transcription Factor Runx2 during Endochondral Ossification. J. Biol. Chem. 2012, 287, 33179–33190. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  211. Lapunzina, P.; Aglan, M.; Temtamy, S.; Caparrós-Martín, J.A.; Valencia, M.; Letón, R.; Martínez-Glez, V.; Elhossini, R.; Amr, K.; Vilaboa, N.; et al. Identification of a Frameshift Mutation in Osterix in a Patient with Recessive Osteogenesis Imperfecta. Am. J. Hum. Genet. 2010, 87, 110–114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  212. Offiah, A.C.; Hall, C.M. The Radiologic Diagnosis of Skeletal Dysplasias: Past, Present and Future. Pediatr. Radiol. 2020, 50, 1650–1657. [Google Scholar] [CrossRef] [PubMed]
  213. Calder, A.D.; Irving, M. Pediatric Radiology in the Diagnosis and Management of Skeletal Dysplasias—Welcome to the Era of Genomic Medicine and Modern Drug Pipelines. Pediatr. Radiol. 2020, 50, 1648–1649. [Google Scholar] [CrossRef] [PubMed]
  214. Schirwani, S.; Campbell, J. Genetics for Paediatric Radiologists. Pediatr. Radiol. 2020, 50, 1680–1690. [Google Scholar] [CrossRef]
  215. Marzin, P.; Cormier-Daire, V. New Perspectives on the Treatment of Skeletal Dysplasia. Ther. Adv. Endocrinol. 2020, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Ijms 22 04321 g001 550
Figure 1. HH and PTHrP signaling pathways in chondrocyte and osteoblast differentiation (A) HH ligands interact with PTCH 1 receptor causing the activation of the SMO protein and in consequence, the activation of GLI transcriptor factors. HH signaling positively regulates the first steps of chondrogenesis from mesenchymal stem cells (MSC) and chondrocyte proliferation. It induces the specification of osteoblast precursors and the maturation in mature osteoblasts. The activation of the GLI3 repressor (GLI3R) inhibits osteoblast precursor proliferation. (B) PTHrP or PTHLH bind to PTHR1 activating Gαs and Gαq proteins. Through Gαs, PTHrP activates adenylate cyclase and the production of cAMP, which in turn activates PKA proteins inducing chondrocyte proliferation and inhibiting their hypertrophic differentiation. However, through Gαq, PTHrP activates PLCβ and the production of DAG and IP3, leading to the activation of PKC and to an increase of intracellular Ca2+, respectively. PLCβ signaling inhibits chondrocyte proliferation and induces their hypertrophic differentiation and osteoblast differentiation.
Figure 1. HH and PTHrP signaling pathways in chondrocyte and osteoblast differentiation (A) HH ligands interact with PTCH 1 receptor causing the activation of the SMO protein and in consequence, the activation of GLI transcriptor factors. HH signaling positively regulates the first steps of chondrogenesis from mesenchymal stem cells (MSC) and chondrocyte proliferation. It induces the specification of osteoblast precursors and the maturation in mature osteoblasts. The activation of the GLI3 repressor (GLI3R) inhibits osteoblast precursor proliferation. (B) PTHrP or PTHLH bind to PTHR1 activating Gαs and Gαq proteins. Through Gαs, PTHrP activates adenylate cyclase and the production of cAMP, which in turn activates PKA proteins inducing chondrocyte proliferation and inhibiting their hypertrophic differentiation. However, through Gαq, PTHrP activates PLCβ and the production of DAG and IP3, leading to the activation of PKC and to an increase of intracellular Ca2+, respectively. PLCβ signaling inhibits chondrocyte proliferation and induces their hypertrophic differentiation and osteoblast differentiation.
Ijms 22 04321 g001
Ijms 22 04321 g002 550
Figure 2. WNT and NOTCH signaling pathways in chondrocyte and osteoblast differentiation. (A) WNT ligands bind to the FZD receptors with or without specific co-receptors like LRP5, LRP6 and ROR2. In the canonical pathway, WNT binding activates the translocation of β-catenin in the nucleus. This inhibits the first step of chondrogenesis but induces the chondrocyte hypertrophic differentiation and osteoblast differentiation and maturation. The non-canonical pathways, through the activation of DVL, JNK and PLC proteins, activate PKC and induce chondrocyte proliferation. WNT signaling can be negatively regulated by extracellular inhibitors, such as SOST, GREM1 and SFRP4, and by intracellular inhibitors, like AMER1. (B) In the NOTCH pathways, DLL or JAG ligands bind to NOTCH receptor and cause consequent proteolytic cleavages resulting in the release of NICD which translocate in the nucleus and interact with MAML1 and RBPJk proteins. NOTCH signaling inhibits chondrogenesis, and the first and the last stages of osteoblast differentiation, but promotes the differentiation of osteoprogenitors in osteoblast precursors.
Figure 2. WNT and NOTCH signaling pathways in chondrocyte and osteoblast differentiation. (A) WNT ligands bind to the FZD receptors with or without specific co-receptors like LRP5, LRP6 and ROR2. In the canonical pathway, WNT binding activates the translocation of β-catenin in the nucleus. This inhibits the first step of chondrogenesis but induces the chondrocyte hypertrophic differentiation and osteoblast differentiation and maturation. The non-canonical pathways, through the activation of DVL, JNK and PLC proteins, activate PKC and induce chondrocyte proliferation. WNT signaling can be negatively regulated by extracellular inhibitors, such as SOST, GREM1 and SFRP4, and by intracellular inhibitors, like AMER1. (B) In the NOTCH pathways, DLL or JAG ligands bind to NOTCH receptor and cause consequent proteolytic cleavages resulting in the release of NICD which translocate in the nucleus and interact with MAML1 and RBPJk proteins. NOTCH signaling inhibits chondrogenesis, and the first and the last stages of osteoblast differentiation, but promotes the differentiation of osteoprogenitors in osteoblast precursors.
Ijms 22 04321 g002
Ijms 22 04321 g003 550
Figure 3. TGFβ, BMP and FGF signaling pathways in chondrocyte and osteoblast differentiation. (A) TGF-β ligands bind to TGFBR type 1 and 2 causing the phosphorylation of the receptors and of SMAD 2 and 3 proteins which interact with SMAD4. This complex accumulates in the nucleus and induces chondrogenesis and osteoblastogenesis but inhibits the last step of chondrocyte and osteoblast maturation. SMAD activity can be blocked by intracellular inhibitors like SKI and LEMD3. (B) BMP ligands bind to BMPR type 1 and 2 causing the phosphorylation of the receptors and of SMAD 1, 5 and 8 proteins which interact with SMAD4. This complex accumulates in the nucleus and induces chondrocyte proliferation and all the steps of osteoblast differentiation. GDF ligands and the NOGGIN antagonist also bind BMPR. (C) FGF ligands bind FGFR causing receptor transphosphorylation, the phosphorylation of the adaptor protein FRS2α and the activation of STAT1, PLCγ and GRB2. GRB2 in turn activates PI3K and MAPK proteins. Through these pathways, FGF promotes chondrocyte proliferation and differentiation in the first step of the development and it promotes osteoblast proliferation and differentiation. In contrast, in the later stages of development, it inhibits chondrocyte proliferation and differentiation. MAPK signaling, downstream of FGFR, can be negatively regulated by the CNP-NPR pathway.
Figure 3. TGFβ, BMP and FGF signaling pathways in chondrocyte and osteoblast differentiation. (A) TGF-β ligands bind to TGFBR type 1 and 2 causing the phosphorylation of the receptors and of SMAD 2 and 3 proteins which interact with SMAD4. This complex accumulates in the nucleus and induces chondrogenesis and osteoblastogenesis but inhibits the last step of chondrocyte and osteoblast maturation. SMAD activity can be blocked by intracellular inhibitors like SKI and LEMD3. (B) BMP ligands bind to BMPR type 1 and 2 causing the phosphorylation of the receptors and of SMAD 1, 5 and 8 proteins which interact with SMAD4. This complex accumulates in the nucleus and induces chondrocyte proliferation and all the steps of osteoblast differentiation. GDF ligands and the NOGGIN antagonist also bind BMPR. (C) FGF ligands bind FGFR causing receptor transphosphorylation, the phosphorylation of the adaptor protein FRS2α and the activation of STAT1, PLCγ and GRB2. GRB2 in turn activates PI3K and MAPK proteins. Through these pathways, FGF promotes chondrocyte proliferation and differentiation in the first step of the development and it promotes osteoblast proliferation and differentiation. In contrast, in the later stages of development, it inhibits chondrocyte proliferation and differentiation. MAPK signaling, downstream of FGFR, can be negatively regulated by the CNP-NPR pathway.
Ijms 22 04321 g003
Table
Table 1. Signaling pathways involved in bone development and associated skeletal dysplasia.
Table 1. Signaling pathways involved in bone development and associated skeletal dysplasia.
Signaling Pathway/Transcription FactorAssociated DiseaseGene(s)OMIM Number
HHWerner syndromeSHH188,740
AcheiropodiaSHH200,500
Preaxial polydactyly type 1 (PPD1)SHH174,400
Preaxial polydactyly type 2 (PPD2)SHH174,500
Syndactyly type 4 (I-V) Haas typeSHH186,200
Laurin-Sandrow syndromeSHH135,750
Preaxial polydactyly type 4 (PPD4)GLI3174,700
Pallister-Hall syndromeGLI3146,510
Grieg cephalopolysyndactylyGLI3175,700
Acrocapitofemoral dysplasiaIHH607,778
Syndactyly with craniosynostosis (Philadelphia type)IHH185,900
Syndactyly Lueken typeIHH
Brachydactyly type A1IHH112,500
PTHrPBlomstrand dysplasia PTHR1215,045
Metaphyseal dysplasia, Jansen typePTHR1156,400
Eiken dysplasia PTHR1600,002
Acrodysostosis PDE4D
PRKAR1A		614,613
101,800
Brachydactyly type EPTHLH613,382
Signaling pathway/Transcription factorAssociated diseaseGene(s)OMIM number
PTHrPPseudohypoparathyroidism type IA (Albright hereditary osteodystrophy)GNAS103,580
Fibrous dysplasia, polyostotic form
(McCune–Albright)		GNAS174,800
Brachydactyly–mental retardation syndromeHDAC4600,430
WNTOsteogenesis imperfecta, progressively deforming type (OI type 3)WNT1615,220
Osteogenesis imperfecta, moderate form (OI type 4)WNT1615,220
Tetra-amelia syndrome type 1WNT3273,395
Robinow syndrome dominant typeWNT5A180,700
Acro-pectoro-vertebral dysplasia (F-syndrome)WNT6102,510
Al-Awadi Raas-Rothschild limb-pelvis hypoplasiaaplasiaWNT7A276,820
Furhmann syndrome WNT7A228,930
Split-hand-foot malformation, isolated form, type 6 (SHFM6)WNT10B225,300
Robinow syndrome recessive type ROR2268,310
Brachydactyly type BROR2113,000
Cenani-Lenz syndactyly LRP4212,780
Osteoporosis-pseudoglioma syndromeLRP5259,770
OsteosclerosisLRP5144,750
Osteoporosis-AD formLRP5
WNT1		166,710
615,220
Osteopetrosis type 1LRP5607,634
Sclerosteosis SOST
LRP4		269,500
614,305
Signaling pathway/Transcription factorAssociated diseaseGene(s)OMIM number
WNTEndostheal hyperostosis, van Buchem typeSOST239,100
Craniodiaphyseal dysplasiaSOST122,860
Cenani-Lenz-like non-syndromic bilateral oligosyndatylyGREM1
Pyle diseaseSFRP4265,900
Osteopathia striata with cranial sclerosis (OSCS)AMER1300,373
Tetra-amelia syndrome type 2RSPO2618,021
Omodysplasia type 1GPC6258,315
NOTCHSpondylocostal dysostosis DLL3
MESP2
HES7
LFNG		277,300
608,681
613,686
609,813
Vertebral segmentation defect (congenital scoliosis) with variable penetranceMESP2
HES7		608,681
613,686
Hajdu-Cheney syndrome NOTCH2102,500
Adams-Oliver syndrome NOTCH1
DLL4
RBPJ		616,028
616,589
614,814
BMP/TGFβMultiple synostoses syndrome NOG
GDF5
GDF6		186,500
610,017
617,898
Brachydactyly type B2NOG611,377
Klippel-Feil syndrome GDF6118,100
Acromesomelic dysplasia (Grebe dysplasia)GDF5
BMPR1B		200,700
609,441
Acromesomelic dysplasia (Fibular hypoplasia and complex brachydactyly, Du Pan)GDF5
BMPR1B		228,900
Signaling pathway/Transcription factorAssociated diseaseGene(s)OMIM number
BMP/TGFβDiaphanospondylodysostosis BMPER608,022
Fibrodysplasia ossificans progressive (FOP)ACVR1135,100
Diaphyseal dysplasia Camurati Engelmann TGFB1131,300
Myhre syndromeSMAD4139,210
Loeys-Dietz syndrome (types 1–6) TGFBR1
TGFBR2
SMAD3
TGFB2
TGFB3
SMAD2		609,192
610,168
613,795
614,816
615,582
601,366
Brachydactyly type A2BMPR1B
BMP2
GDF5		112,600
112,600
112,600
Brachydactyly type CGDF5113,100
OsteopoikilosisLEMD3166,700
Melorheostosis with osteopoikilosisLEMD3166,700
Shprintzen–Goldberg syndromeSKI182,212
FGFThanatophoric dysplasia type 1 FGFR3187,600
Thanatophoric dysplasia type 2FGFR3187,601
SADDANFGFR3616,482
AchondroplasiaFGFR3100,800
HypochondroplasiaFGFR3146,000
Camptodactyly, tall stature and hearing loss syndrome (CATSHL)FGFR3610,474
Bent bone dysplasia FGFR2614,592
Osteoglophonic dyplsasia FGFR1166,250
Pfeiffer syndrome FGFR1
FGFR2		101,600
101,600
Jackson-Weiss syndromeFGFR2
FGFR1		123,150
123,150
Apert syndrome FGFR2101,200
Craniosynostosis with cutis gyrata (Beare-Stevenson)FGFR2123,790
Crouzon syndrome FGFR2123,500
Signaling pathway/Transcription factorAssociated diseaseGene(s)OMIM number
FGFSaethre–Chotzen syndromeFGFR2
Crouzon-like with achantosis nigricans FGFR3612,247
Craniosynostosis Muenke type FGFR3602,849
Multiple synostosis syndrome type 3 FGF9612,961
Hartsfield syndrome FGFR1615,465
Lacrimo-auriculo-dento-digital syndrome (LADD) FGFR2
FGFR3
FGF10		149,730
Hyperostosis–Hyperphosphatemia syndromeFGF23617,993
Acromesomelic dysplasia type MaroteauxNPR2602,875
Tall stature with long halluces, NPR2 typeNPR2615,923
SOX9Campomelic dysplasiaSOX9114,290
RUNX2Metaphyseal dysplasia with maxillary hypoplasiaRUNX2156,510
Cleidocranial dysplasiaRUNX2119,600
SP7/OsterixOsteogenesis imperfecta, moderate form (OI type 4)SP7613,849
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Guasto, A.; Cormier-Daire, V. Signaling Pathways in Bone Development and Their Related Skeletal Dysplasia. Int. J. Mol. Sci. 2021, 22, 4321. https://doi.org/10.3390/ijms22094321

AMA Style

Guasto A, Cormier-Daire V. Signaling Pathways in Bone Development and Their Related Skeletal Dysplasia. International Journal of Molecular Sciences. 2021; 22(9):4321. https://doi.org/10.3390/ijms22094321

Chicago/Turabian Style

Guasto, Alessandra, and Valérie Cormier-Daire. 2021. "Signaling Pathways in Bone Development and Their Related Skeletal Dysplasia" International Journal of Molecular Sciences 22, no. 9: 4321. https://doi.org/10.3390/ijms22094321

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop